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ABSTRACT 
Endometrial (ECa), ovarian (OCa) and cervical (CCa) cancers are among ten of 
the most common cancers affecting women worldwide.  Cancers are known to cause 
some proteins to be differentially glycosylated or aberrantly excreted in the urine, which 
can be used as biomarkers.  Since ECa, OCa and CCa are difficult to diagnose at the 
early stage, the aim of the present study was to identify a panel of new complementary 
biomarkers for early detection of the cancers.  Identification of early biomarkers which 
are specific and efficient can increase the survival rate of the patients. 
 
To screen for potential biomarkers for ECa, separation of urinary proteins of 
control subjects and patients with ECa by 2-DE and densitometry analysis were 
performed.  The analysis of 2-DE urinary profiles of controls and patients with ECa 
demonstrated significant differential expression of zinc-alpha 2 glycoprotein (ZAG), 
acid alpha-1 glycoprotein (AAG) and CD59.  When similar 2-DE analysis was 
performed using CGB lectin-Western blotting approach to detect O-glycosylated 
urinary proteins, the level of nebulin (NEB) was detected to be reduced in the ECa 
patients compared to the controls.  Using similar analysis with CGB lectin, the altered 
levels of kininogen (KNG), clusterin (CLU) and leucine rich alpha-2 glycoprotein 
(LRG) were also demonstrated in the patients with OCa.  However, the expression 
levels of all O-glycosylated proteins appeared to be comparable in patients with CCa. 
 
A significant increase in the levels of urinary ZAG and AAG was detected in 
ECa patients when the 2-DE profiles were transferred onto membrane and  probed with 
CMB lectin to exclusively capture N-glycosylated urinary proteins.  Similar 
comparative analysis of the N-glycosylated protein profiles performed on OCa patients 
demonstrated overexpression of AAG, ZAG, LRG, CLU and HPβ chain but decreased 
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in the levels of  KNG.  Comparable expression of N-glycosylated urinary proteins was 
detected between the controls and CCa patients.   
 
Analysis of bound fractions obtained from immoblilized CGB lectin affinity 
chromatography followed by the labeled-free quantification showed differential levels 
of LRG and NEB in patients with OCa and ECa, respectively.  This is comparable with 
the earlier data obtained from CGB lectin probed Western blot.  Similarly, spectral 
counting of the N-glycosylated proteins isolated by immobilized CMB lectin affinity 
chromatography demonstrated altered levels of AAG and ZAG for patients with ECa 
and OCa and differential expression of KNG and HPβ chain for OCa patients, which are 
also compatible with the findings using CMB lectin blot.  In addition, the LC-MS/MS 
analysis of the CMB lectin bound fractions detected CD59 peptides only in the controls 
but not in patients with ECa, OCa and CCa. 
 
When SELDI-TOF and Biomarker Wizard analyses were carried out on the 
CMB lectin captured urinary glycopeptides from control subjects and patients with ECa, 
OCa and CCa, peaks m/z 1201 and 1449 were detected as potential group 
discriminators. Similarly, the analysis performed on the CGB lectin captured urinary 
glycopeptides from control subjects and the three groups of cancer patients predicted 
peaks m/z 2138 and 3656 as potential group discriminators. 
 
Taken together, the findings of this study suggest urinary proteins such as ZAG, 
AAG, NEB, KNG, LRG, CLU, HPβ chain and CD59 may serve as potential 
complementary biomarkers for the early detection of ECa, OCa and CCa although this 
requires further extensive validation on clinically representative populations. 
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ABSTRAK 
Kanser endometrium (ECa), ovari (OCa) dan serviks (CCa) adalah di antara 
sepuluh kanser yang paling lazim melibatkan wanita di seluruh dunia.  Kanser 
sememangnya diketahui menyebabkan sesetengah protein mengalami perubahan 
pengglikosilan atau dikumuhkan melalui air kencing, yang boleh diguna sebagai 
penanda biologi.  Disebabkan ECa, OCa dan CCa adalah sukar untuk didiagnosis pada 
peringkat awal, tujuan kajian ini adalah untuk mengenalpasti satu panel penanda biologi 
pelengkap baru untuk mengesan kanser pada peringkat awal.  Pengenalpastian penanda 
biologi baru yang spesifik dan berkesan boleh meningkatkan kadar kemandirian pesakit. 
 
Untuk menyaring penanda biologi yang berpotensi bagi ECa, pengasingan 
protein air kencing daripada subjek kawalan dan pesakit ECa dilaksanakan dengan 
menggunakan kaedah 2-DE dan analisis densitometry.  Analisis menunjukkan 
perbezaan ketara dalam pengekspresian zink-alfa 2 glikoprotein (ZAG), asid alfa-1 
glikoprotein (AAG) dan CD59.  Apabila  kaedah 2-DE yang sama dilakukan dengan 
menggunakan kaedah pemblotan Western-lektin CGB untuk mengesan protein air 
kencing yang O-terglikosilat, paras nebulin (NEB) dikesan berkurangan dalam pesakit 
ECa berbanding subjek kawalan.  Dengan menggunakan kaedah yang sama dengan 
lektin CGB, penjejasan pengekspresian kininogen (KNG), klusterin (CLU) dan 
glikoprotein kaya leusina alfa-2 (LRG) turut ditunjukkan berubah dalam kajian yang 
sama. Walau bagaimanapun, tahap pengekspresian kesemua protein O-terglikosilat 
kelihatan setanding dalam  pesakit CCa. 
 
Peningkatkan aras ZAG dan AAG air kencing dikesan berlaku dalam pesakit 
ECa apabila profil 2-DE dipindahkan ke atas membran dan disurih dengan lektin CMB 
untuk mengesan protein N-terglikosilat secara eksklusif.  Analisis sama yang dilakukan 
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pada profil protein N-terglikosilat pesakit OCa menunjukkan peningkatan 
pengekspresian protein AAG, ZAG, LRG, CLU dan HPβ tetapi penurunan aras KNG.  
Walau bagaimana pun, aras pengekspresian kesemua protein air kencing N-terglikosilat 
adalah setanding bagi pesakit CCa. 
 
Analisis pecahan berikat yang diperoleh daripada kromatografi keafinan lektin 
CGB diikuti dengan kuantifikasi bebas label menunjukkan pembezaan aras LRG dan 
NEB masing-masing dalam pesakit OCa dan ECa.  Ini adalah serasi dengan penemuan 
yang dihasil menggunakan “Western blot” yang disurih lektin CGB.  Begitu juga, 
pengiraan spektrum protein N-terglikosilat yang diasing menggunakan kromatografi 
keafinan lektin CMB menunjukkan perubahan ketara aras AAG dan ZAG dalam pesakit 
ECa dan OCa dan perbezaan pengekspresian KNG dan HPβ dalam pesakit OCa, yang 
juga serasi dengan penemuan menggunakan blot lektin CMB.  Selain itu, analisis LC-
MS/MS terhadap pecahan berikat lektin CMB mengesan kewujudan CD59 hanya di 
dalam subjek kawalan dan tidak terdapat dalam pecahan yang dikumpul daripada 
pesakit ECa, OCa dan CCa. 
 
Apabila analisis  SELDI-TOF dan Biomarker Wizard dijalankan terhadap 
glikopeptida air kencing pesakit ECa, OCa dan CCa yang terikat kepada lektin CMB, 
puncak m/z 1201 dan 1449 dikesan sebagai kumpulan pembeza yang berpotensi.  Begitu 
juga, analisis yang dilakukan ke atas glikopeptida yang diikat oleh lektin CGB daripada 
subjek kawalan dan tiga kumpulan pesakit kanser turut meramalkan m/z 2138 dan 3656 
sebagai kumpulan pembeza yang berpotensi. 
 
Apabila dikumpulkan, hasil kajian ini mencadangkan protein air kencing seperti 
ZAG, AAG, NEB, KNG, LRG, CLU, rantaian HPβ dan CD59 berpotensi untuk 
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digunakan sebagai penanda biologi awal untuk pengesanan ECa, OCa dan CCa 
walaupun ini memerlukan pengesahan selanjutnya dalam populasi klinikal. 
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CHAPTER  1: INTRODUCTION   
1.1 Lectins 
 
1.1.1 History of lectin 
Lectin was first discovered by Hermann Stillmark in 1888 when he described 
the agglutination properties of ricin that was extracted from the seeds of castor bean 
(Ricinus communis) of the family of Euphorbaceace (Damme 2008).  Later in 1919, the 
lectin research gained momentum when James B. Sumner was able to purify and 
crystallize hemagglutinin from Jack bean (Canavalia ensiformis), which he named 
concanavalin A (Con A)  Sumner found that Con A can bind and agglutinate red blood 
cells and precipitate glycogen, mucins and starch (Sumner and Howell, 1936).  In 1954, 
Boyd and Shapleigh introduced the term “lectin” which was derived from the Latin 
word “legere”, meaning “to select” or “to gather” (Hamid et al., 2013).  They identified 
that the lectin extracted from lima bean (Phaseolus lunatus limensis) was able to bind 
and agglutinate human red blood cells of the A-type blood group.    
 
Initially, lectin is defined as a sugar binding protein of non-immune origin which 
is able to agglutinate cells or precipitate glycoconjugates (Goldstein et al., 1980)  
However, this definition was expanded to a more concise description for lectins as more 
lectins with different properties and capabilities were discovered.  Therefore, lectin is 
later denoted as a protein that are non-immunoglobulins capable of specific recognition 
and reversible binding to carbohydrate moieties of complex carbohydrate without 
altering the covalent structure of any of the recognized glycosyl ligands (Kocourek and 
Horejsi, 1983).  Currently, a simple definition is used to describe lectin as a 
carbohydrate-binding protein other than an enzyme or an antibody. 
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1.1.2 Plant lectins: function, localization and classification  
Lectins can be found in a variety of life ranging from microorganisms such as 
viruses and bacteria to plants and animals.  They have similar functions regardless of 
their origin.  Additionally, they share a similar binding property toward carbohydrate 
although they show no homology in primary structure.  Through structural elucidation, 
their binding property was found to be contributed by their tertiary structure, 
carbohydrate-recognition domain by recognizing the terminal non-reducing 
carbohydrates residues and the anomeric isomers of glycoproteins (Ghazarian et al., 
2011).  Generally, they are ubiquitous in plants, especially from the genus of 
Euphorbiaceae and Leguminoseae.  They can be found in roots, tubers, bulbs, leaves, 
flowers, rhizomes, fruits, stems and seeds.  Among these sources, it is more abundant in 
the seeds, the storage organs of plants. 
  
At present, there are three approaches to classify plant lectins.  The first 
classification has been adopted based on the origin, structurally and evolutionally 
related to the plant lectin.  Under this classification, lectins  can be divided into seven 
distinct families, which include Amaranthin lectins, chitin-binding lectins, 
Cucurbitaceae phloem lectins, jacalin related lectins, legume lectins, monocot mannose-
binding lectins and type-2 ribosome-inactivating proteins (Van Damme et al., 2004).   
 
The second classification method involves the division of lectins into four 
classes according to their physical structure.  The four classes are merolectin, hololectin, 
chimerolectin and superlectin (Vandenborre et al., 2011).  Merolectins are monovalent 
proteins that consist of a single carbohydrate binding domain.  Due to their monovalent 
property, they are unable to precipitate glycoconjugates or agglutinate cells.  
Hololectins are lectins that contain at least two homologous or identical carbohydrate-
Introduction 
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binding domains.  They are able to bind and precipitate glycans because of their 
multiple binding sites.  The third class of lectins is chimerolectins which refers to those 
proteins that contain a carbohydrate-binding domain arrayed tandemly with an unrelated 
domain.  Their unrelated domain contributes to the catalytic activity that acts 
independently on the carbohydrate binding domain.  Superlectins consist of two 
carbohydrate-binding domains that recognize structurally unrelated sugars.  They can be 
considered as a special type of chimerolectins composed of two tandemly arrayed 
structurally and functionally different carbohydrate-binding domains. 
 
The last method of classification is based on lectin’s complementary to the 
carbohydrate groups.  Different lectins have their own specificity to the carbohydrate 
groups.  Therefore, plant lectins are divided into five subgroups according to their 
specificity to the monosaccharide.  They are glucose and/or mannose (Glc and/or Man) -
specific, galactose and/or N-acetylgalactosamine (Gal and/or GalNAc)-specific, N-
acetylglucosamine (GlcNAc)-specific, L-fucose (L-Fuc)-specific and sialic acid 
(Goldstein and Poretz, 1986). 
 
Owing to their capabilities of recognizing diverse sugar structures, they mediate 
a variety of biological processes.  One of the most important functions exhibited by 
plant lectins is to serve as plant storage proteins as they are abundant in seeds and 
vegetative storage tissues (Van Damme et al., 1995).  Besides, it also functions as a 
protector to defend against phytopathogens (virus, bacteria and fungi) and insects 
(Peumans and Van Damme 1995).  It defends against these invasions through indirect 
mechanisms, which involved interactions with the cell wall carbohydrate or 
extracellular glycans (Peumans and Van Damme 1995).  Lectin is also involved in 
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rhizobium-legume interaction, in which the fixation of nitrogen occurs through the 
symbiosis interaction of the bacteria and the plant roots (Diaz et al., 1989).  
 
Other than these three main functions, lectins have also been shown to have 
various other physiological functions such as in the cell wall extension, maintaining 
seed dormancy, mitogenic stimulation of embryonic plant cells, cell recognition 
between pollen and stigma or style, transporting marcomolecules and packaging or 
mobilizing the storage materials during the seeds maturation or germination 
(Vandenborre et al., 2011). 
 
1.1.3    Application of plant lectins 
The specificity of lectins to recognize particular carbohydrate structures enables 
them to be used as a tool for various researches.  Table 1.1 shows examples of plant 
lectins and their affinities.  Lectins are easily available because they are abundant in 
plant seeds.  In addition,  they are less expensive, better characterized with respect to 
binding specificity and more stable as compared to antibody (Etzler, 1979).  Currently, 
lectins are extensively used to investigate the biological and pathological significance of 
glycosylation (Dennis et al., 1999; Ghazarian et al., 2011).  Because of their capabilities 
of differentiating the carbohydrate residues available on the blood cells surface, some 
plant lectins are being used for blood group typing and cell typing.  For instance, lectin 
isolated from Phaseolus limensis is used to identify type A blood cell while lectins 
purified from Dolichos biflorus is able to differentiate A1 blood subgroups (Nakajima et 
al., 1986; Sharon and Lis 2004).  Meanwhile, lectin obtained from Lotus tetragonolobus 
could identify type O blood cells (Renkonen, 1948).  Lectins from Vicia graminea is 
used to distinguish between the N blood group and the M blood group as it recognizes 
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only N blood group (Duk et al., 1981).  The H blood group antigen is able to be 
identified by lectin of Ulex europaeus (Engelmann, 1993). 
 
Table 1.1: Examples of plant lectins and their affinity  (Dai et al., 2009)  
Name/ Abbreviation Origin Affinity 
LCA Lens culinaris Fucα1-6GlcNAc and α-Man, α-Glc 
PSA Pisum sativum 1,6-Fucosylation of the trimannosyl 
core and α-Man. 
AAL Aleuria aurantia Fucα1-6-GlcNAc, Fucα1,3/1,4-
GlcNAc, Fucα1,2-Gal 
AAA Anguilla Anguilla Fuc linked to the GlcNAc 
LTA Lotus tetragonolobus Fucα1,3/1,4-GlcNAc, Fucα1,2-Gal, 
Le
x 
ConA Concanavalin 
ensiformis 
Two nonsubstituted or C2-substituted 
α-mannopyranosyl residues in one 
molecule 
Jacalin Artocarpus 
integrifolia 
O-linked oligosaccharide; α-D-
Gal,Gal(β-1,3)GalNAc 
 
 
Apart from that, plant lectins’ agglutination property enables them to be used as 
diagnostic probes to identify bacteria.  For example, the ability of detecting Neisseria 
and Bacillus species by wheat germ agglutinin (WGA) lectin and soybean agglutinin 
(SBA), respectively, has been utilized in  the development of a diagnostic kit to 
differentiate the respective species within the same genus (Schalla et al., 1985).  
 
Plant lectins could also be used in studying and characterizing the structure of 
glycoconjugates.  Aberrant glycosylation structures are usually associated with the 
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disease progression.   In order to examine the alteration of disease-related glycosylation, 
several analytical methods are utilized including lectin affinity chromatography coupled 
with mass spectrometry.  In general, glycoproteins are isolated from the complex 
biological samples on the basis of their specific carbohydrare group which could be 
recognized by their respective lectins.  For example, Zhao and his coworkers used three 
types of lectins, including WGA, Elderberry lectin and Maackia amurensis lectin that 
were immobilized to generate affinity chromatography to purify sialylated glycoproteins 
from sera of normal subjects and patients with pancreatic cancer (Zhao et al., 2006).  
This was followed by characterization of the glycoproteins and glycans using the mass 
spectrometry.  In addition, lectin affinity fractionation coupled with 2-dimensional 
electrophoresis (2-DE) was used to identify different isoforms of prostate cancer antigen 
in the serum samples of patients with prostate cancer (Sumi et al., 2001).  
 
Lectins have also been shown to have the ability to stimulate the division of 
cells, especially mononuclear cells.  For example, lymphocytes cells divide when 
stimulated with the mitogenic lectin phytohemagglutinin (Cass, Pham et al.) (Reed et 
al., 1986).  Therefore, they are used in the diagnostic tools for lymphoid tissue diseases.  
An example of this application has been demonstrated when the acute lymphoblastic 
leukemia was diagnosed by characterizing the immunological phenotype of malignant 
lymphoid cells and distinguishing the cytological variants of acute lymphoblastic 
leukemia and lymphomas of lymphatic cells (Gluzman et al., 1991). 
 
 Lectins have also played an important role in biomedical and pharmacological 
fields.  Some of the plant lectins such as abrin, cytotoxic A-chains of ricin and purified 
mistletoe lectin ML-I have been used in therapeutic agents for cancer because of  their 
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antitumor cytotoxin activity where they can inhibit protein synthesis with high efficacy 
(Lord et al., 1991; Tonevitsky et al., 1991; Paprocka et al., 1992).  They have also been 
used to serve as carriers in targeted therapy for cancer where they are conjugated to 
drugs and targeted to specific tumors (Bonfils et al., 1992; Mody et al., 1995)  
Meanwhile, plants lectins such as Urtica dioica agglutinin, Galanthus nivalis 
agglutinin, Astrocarpus heteophyllus agglutinin, Myrianthus holstii lectin and 
concanavalin A (ConA) lectin were suggested as effective agents to control the course 
of AIDS as they demonstrated to have anti-HIV activities, in vitro  (Witvrouw et al., 
2005). 
 
1.1.4  Champedak  
Artocarpus integer, commonly known as champedak in Malaysia, is classified 
under the Moraceae family and Artocarpus genus.  Champedak is similar to jackfruit 
(Artocarpus heterophillus/ integrifolia), but smaller in size, with less pith, more seeds 
and softer pulp (Abdul Rahman et al., 2002).  The seeds of champedak contain two 
types of lectins which are known as champedak galactose binding lectin (CGB) and 
champedak mannose binding (CMB) lectin.  
 
1.1.4.1  Champedak Galactose-binding (CGB) Lectin 
Champedak galactose-binding (CGB) lectin recognizes the structure Galβ1-
3GalNAc of IgA1 and C1 inhibitor (Hashim et al., 1991).  It was demonstrated to have 
haemagglutinating activity against human erythrocytes of blood groups A, B, AB and O 
(Abdul Rahman et al., 2002).  In addition, it was able to compensate the complement 
and thus decrease the complement-mediated hemolytic activity of sensitized sheep 
erythrocytes (Hashim et al., 1994).  Currently, the lectin has been used as a probe to 
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study the serum or urinary glycoproteins of several malignancies (Abdul-Rahman et al., 
2007; Mohamed et al., 2008; Jayapalan et al., 2012; Mu et al., 2012; Mu et al., 2013).  
 
The structure and properties of the CGB lectin are generally identical to jacalin, 
a lectin of jackfruit.  However, the CGB lectin from different clones of champedak 
seeds were demonstrated to be structurally and functionally similar but jacalin from 
diverse cultivars of jackfruits varied in their structures and functional activities (Hashim 
et al., 1991).  The CGB lectin comprises two types of non-convalently linked subunits 
with Mr of 13000 and 16000 Da.  When it was subjected into reverse-phase high 
performance liquid chromatography (HPLC), the lectin resolved into two major (α and 
β1) and one minor (β2) peaks (Abdul Rahman et al., 2002).  The α and β subunits 
contain 133 and 21 amino acid residues, which are non-identical from each other, 
respectively (Gabrielsen et al., 2009).  The first 47 amino acids residues of the N-
terminal sequence of the α subunit showed close sequence homology with that of  
jacalin. 
 
Both the β1 and β2 subunits have the same number of amino acid residues but 
different in four residues at positions 6, 10, 12 and 19.  They share more than 70% 
sequence homology with the β subunits of other galactose-binding lectins from other 
Artocarpus species.  Both β subunits lack cystein residue in their sequence leading to 
the failure of interchain or intrachain disulphide bond formation. 
 
1.1.4.2  Champedak Mannose-binding (CMB) Lectin 
Champedak mannose binding (CMB) lectin is a homotetramer with a single 
monomer with a molecular weight of 16800 Da.  It has quite a similar structure with 
artocarpin (the jackfruit mannose binding lectin) but they were not identical due to the 
Introduction 
9 
 
presence of disulphide linkage in the CMB lectin (Lim et al., 1998).  The CMB lectin 
was shown to interact strongly with human IgE and IgM but interact weakly with IgA2 
(Gabrielsen et al., 2010).  In addition, it also demonstrated a strong interaction with 
core-mannosyl residues of the N-linked oligosaccharides of glycoproteins such as α1-
antitrypsin, haptoglobin β chain, orosomucoid, α1β-glycoprotein, ovalbumin, porcine 
thyroglobulin, human α1-acid glycoprotein and transferrin (Hashim et al., 2001).  Man 
α1-3 Man ligand is the preference isomer for the CMB lectin to bind to as compared to 
other two types of isomers (Lim et al., 1998).  The lectin was also shown to have a 
selective mitogenic activity towards T lymphocytes (Lim et al., 1998).  It activates 
murine B cells to secret immunoglobulins, but only in the presence of T cells and 
macrophages (Lim et al., 1998).   
  
1.2       Urinary proteomics   
1.2.1    Definition of proteomics 
Proteomic is the study of protein expression in a tissue or biological fluid 
(Anderson and Anderson 1998).  However, this definition is too general to describe 
proteomics as many different types of approaches are classified under this group other 
than the study of protein expression.   This includes protein-protein interaction, protein 
post-translational modification and protein structure (Anderson et al., 2000; Graves and 
Haystead 2002).  Therefore, a more accurate and decisive definition has termed 
proteomic as a large-scale analytical study of protein properties in obtaining a global, 
integrated view of disease processes, cellular functions and networks at the protein level 
(Blackstock and Weir 1999).  
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1.2.2    Overview of urine analysis 
Compared to other biofluids, urine has several characteristics that makes it a 
preferred choice for biomarker discovery.  Firstly, high amounts of urine are easily and 
non-invasively obtained from the volunteers.  Secondly, the components of the urine are 
similar to those found in the blood.  In healthy individuals, seventy percent of the urine 
proteome is originated from the kidney and the urinary tract, while the remaining is the 
proteins filtered by the glomerulus (Decramer et al., 2008).  Approximately 150 liters of 
plasma is filtered by the glomerulus from a total of 900 liters of plasma flowed through 
the kidneys.  The filtration of the glomerulus is mainly a selective process based on 
dimension, charge and configuration of the protein.  Thus, the urinary proteome can be 
used to detect not only abnormalities within the kidney and the urogenital tract but also 
systemic diseases associated with small circulating proteins and peptides that can pass 
through the glomerulus.  Thirdly, the urinary proteins are relatively stable without 
significant protein degradation.  Previous studies have shown that the urinary proteome 
did not change significantly when urine was stored for three days at 4
o
C, 6 hours at 
room temperature and several years at -20
 o
C (Fliser et al., 2007).  Fourthly, the urinary 
proteome contains minimal amount of high abundance proteins such as albumin and 
IgG compared to serum proteome.  Albumin and IgG sometimes mask the low 
abundance proteins that may have a potential to be a biomarker.  Therefore, this makes 
the analysis of low abundance proteins becomes much easier in urine samples.  
 
Hermogenes has already used the urine’s colour as an indicator for a disease in 
the 5
th
 century (Iorio and Avagliano, 1999).  In addition, a physician Gerrit Dou 
described the meticulous observation of urine by the 17
th
 century (Fliser et al., 2007). 
The first urinary proteomic was applied in analyzing the nature of the normal urinary 
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proteins by Rigas and Heller in 1951 using SDS-PAGE (Fliser et al., 2007).  In 1979, 
Anderson was the first person who studied the normal urine composition using the 2-DE 
technique (Candiano et al., 2010).  The first extensive optimized human urinary 
proteome map was established by Thongboonkerd and his co-workers in 2002 when 
they precipitated the urinary proteins from healthy subjects and analysed with 2-DE 
(Thongboonkerd et al., 2002).  Since then, a number of attempts in defining more 
advance and complete reference maps of normal urinary proteins were undertaken by  
other researchers using various types of proteomic techniques (Oh et al., 2004; Pieper et 
al., 2004; Sun et al., 2005; Casado-Vela et al., 2011; Marimuthu et al., 2011). 
 
1.2.3 Application of urinary proteome analysis in cancer  
Owing to the origin of urine from the renal system, the proteomic analyses have 
been applied in the search of biomarkers for renal diseases, such as glomerular disease, 
acute renal allograft rejection, urological cancers and urolithiasis (Cadieux et al., 2004; 
Schaub et al., 2004a; Thongboonkerd et al., 2004; Goodison et al., 2009; Morrissey et 
al., 2010).  Urological cancers, including bladder cancer and renal cell carcinoma have 
been extensively examined in the last decade by using this approach.  Recently, Chen et 
al. (2010) identified a panel of biomarkers for bladder cancer using the iTRAQ-based 
quantitative profile.  Some of the proteins, such as apoliprotein A-I, apoliprotein A-II, 
heparin cofactor 2 precursor and peroxidase-2, were significantly increased in the urine 
obtained from patients with bladder cancer.  Rogers et al. (2003) defined clinically 
specific biomarkers for renal cell carcinoma using SELDI-TOF analysis, in one training 
and two blinded sets of urine samples from patients.  
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Thirteen percent of the urinary proteins are not originated from the urogenital 
tract.  This is not a surprised since proteomic analysis of the urine has revealed 
biomarkers for several non-renal cancers.  Tantipaiboonwong et al. (2005) analyzed the 
urine obtained from the patients with lung cancer using SDS-PAGE coupled with HPLC 
and 2-DE analyses.  He identified  CD59, transthyretin, GM2 activator protein and Ig-
free light chains as differentially expressed proteins which may have a potential to be 
the panel of biomarkers for lung cancer.  In a separate study, capillary electrophoresis 
coupled with mass spectrometry was used to uncover potential urinary biomarkers for 
prostate cancer (Theodorescu et al., 2008).  The results illustrated that these novel 
biomarkers were secreted into the urine from the prostatic fluid.  Meanwhile, 
gynaecological cancers have also been investigated for urinary protein biomarkers, 
particularly ovarian cancer.  Using 2-DE coupled with mass spectrometry analysis, 
Abdullah-Soheimi et al. (2010) uncovered a fragment of inter- alpha-trypsin inhibitor 
heavy chain 4, a fragment of albumin and kininogen that can be potentially used to 
identify patients with early stage ovarian cancer.  Another study examined the 
feasibility of using urine as a clinical sample to compare and discriminate benign and 
malignant ovarian cancer proteomic profiles with equalizer bead technology combined 
with surface enhanced laser desorption ionization (SELDI-TOF) mass spectrometry 
analysis (Petri et al., 2009).  
 
1.3       Proteomic techniques 
The strategies of search for biomarkers of disease using proteomics have been 
categorized as top-down or bottom-up.  The top-down strategy comprises the separation 
of proteins either with chromatography or 2-DE followed by tryptic digestion and the 
analysis of tryptic peptides using mass spectrometry.  On the other hand, the bottom-up 
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strategies involve the trypsin digestion of proteins into peptides followed by the 
isolation of peptides with chromatography and analysis using mass spectrometry.  The 
techniques used to separate and analyze the proteins include 2-DE coupled with mass 
spectrometry, liquid chromatography coupled to mass spectrometry and SELDI-TOF 
mass spectrometry. 
 
1.3.1    Two-dimensional gel electrophoresis 
Although non-gel-based approaches have been developed, 2-DE still remains the 
most popular and effective technique to study and separate proteins from a sample 
despite being laborious, time-consuming, hard to automate and not applicable for low 
molecular weight proteins.  This technique separates proteins into two dimensions 
according to their isoelectric point and molecular mass.  The first dimension separation 
involves the fractionation of the proteins by electrofocusing.  The proteins migrate to 
their respective isoelectric point in a pH gradient.  This is followed by the separation of 
proteins in a perpendicular dimension, in which the proteins migrate on the basis of 
their molecular weights using SDS-PAGE. 
 
After separation in a 2-DE gel, the proteins are resolved into spot patterns, which 
is often viewed by staining the gel with various staining methods and subsequently 
converted to compatible image file for densitometry analysis.  The volumes of protein 
spots are determined by quantification software.  The differentially expressed proteins 
are identified by mass spectrometry.  The step involves the proteolytic digestion of the 
proteins by exposing gel slices to trypsin, the extraction of the proteolytic fragments 
from the gel slices and the identification of the proteins from the database based on the 
masses of proteolytic fragments as determined by  mass spectrometry.  
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Post-translational modifications have often displayed a broad range of protein 
patterns such as multiple spots or smears in 2-DE gels.  This is because post-
translational modifications confer changes of the isoelectric points and molecular 
weights of the protein.  Therefore,  2-DE proves to be able to resolve proteins that 
underwent high degree of post-translational modifications.  For example, 2-DE 
employed with lectin blotting and lectin affinity chromatography has been used to 
isolate and analyze the serum N-glycosylated proteins obtained from patients with 
nasopharyngeal cancer (Seriramalu et al.,  2010). 
 
1.3.2       Liquid chromatography  
Liquid chromatography (LC) is a powerful tool which has been used in various 
applications including the study of the urinary proteome (Agron et al., 2010; Tan et al.,  
2010).  It has gained popularity nowadays as it provides high sensitivity and selectivity 
towards the analysis.  Using this method, the analytes are initially digested with trypsin 
to form a complexity of the resulting mixture.  The resulting tryptic mixtures are 
fractionated by LC column and later sequenced by compatible mass spectrometer to 
identify the proteins based on the sequence information of the peptide detected. 
 
1.3.3    Mass spectrometry 
Mass spectrometry analysis is the last step of the proteome study after the 
separation step and ionization step.  Generally, a mass spectrometer instrument consists 
of three modules: an ion source, a mass analyser and a detector.  Matrix-assisted laser 
desorption/ionization (MALDI) is one of the most widely used  soft ionization 
technique for the mass spectrometry analysis.  It was first introduced by Franz 
Hillenkamp in 1985 when he found that the amino acid alanine could be ionized easily 
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with mixing of amino acid tryptophan (Karas et al., 1985; Laiko et al., 2000).  It allows 
the analysis of the biomolecules because it does not tend to destruct them by 
vaporization and ionization.  In MALDI analysis, a matrix compound is used to co-
crytallized with the analytes, which plays the role as the proton donor or receptor and 
energy absorbing material.  The ionization process is triggered when a pulsed laser is 
shot on the matrix to cause it to excite and directly vaporize with the analyte.  Finally, 
the ionized molecules are desorpted into the gas phase and entered the mass analyzer. 
 
Basically, there are four types of mass analyzer typically used for the proteome 
analysis: quadrupole (Q), ion-trap, time of flight (TOF) and Fourier transform-ion 
cyclotron resonance (FT-ICR) instruments (Fliser et al., 2007).  The TOF analyzer  is 
normally combined with MALDI instrument.  In the mass analyzer, the ions are 
accelerated by an electric field to “fly” down a flight tube  and a detector at the end of 
the tube records the time of flight of the ions.  The time of flight of the ion is 
proportional to the size of the ion.  Therefore, the mass of the ion (m/z) corresponds to 
the time of flight of the ion. 
 
In order to obtain highly accurate sequence information of tryptic peptides, 
tandem mass spectrometry (MS/MS)  is performed with the compilation of MALDI and 
TOF/TOF instrument.  The first TOF instrument serves as a mass filter to collect the 
parent ions, while the second TOF instrument is used to analyze the daughter ions 
(fragments) that are generated by collision-induced dissociation or electron transfer 
dissociation (Fliser et al.,  2007).  
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The resulting peptides fragment masses were presented as MS data and 
subjected to search by engines such as MASCOT, SEQUEST, ProFound or Spectrum 
Mill.  Currently, there are two frequently used databases which are the Swiss-Prot and 
the International Protein Index (IPI).  The search engine compares the MS data against 
the database consisting of the amino acid sequence masses to form a list of protein with 
high probability of correct identification. 
 
1.3.4    Surface enhanced desorption/ionization  mass spectrometry 
SELDI which employed chromatography and mass spectrometry was introduced 
by Hutchens and Yip in 1993 (Hutchens and Yip 1993).  It has emerged as one of the 
most popular mass spectrometry based techniques for biomarker discovery because of 
its ease of use, high throughput, automation and the capability to analyze multiple 
samples in small volumes in a short time.  Basically, it consists of three major 
components:  the ProteinChip array, the ProteinChip reader and the ProteinChip 
software.  The analysis of a sample using SELDI is aimed to reduce the sample 
complexity by selectively capturing proteins by different active surfaces of an array.  
There are two main types of active surfaces, which are the chemical surface and pre-
activated biochemical surface.  
 
In general, a protein sample is added to the protein array and incubated for a 
certain period.  Only a subset of proteins in the sample binds to the protein chip while 
the unbound proteins are washed away.  A matrix is added to the chip to co-crystallized 
with the bound proteins and subsequently proceed to the ProteinChip Reader. 
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The ProteinChip Reader is a laser desorption ionization time of flight mass 
spectrometry instrument equipped with a pulsed ultraviolet nitrogen laser source that 
uses state-of-the-art ion optic and laser optic technology.  The ionization and desorption 
processes that occur in the ProteinChip Reader are similar to the MALDI-TOF.  
Eventually, the detected proteins are presented as a series of peak with m/z values and 
intensities.  
 
The ProteinChip Software is used to control the functions of the ProteinChip 
Reader and facilitates data collection and processing.  This includes the loading of the 
ProteinChip array into the equipment, calibrating the reader, analyzing the samples, 
normalizing spectra and presenting the data. 
 
1.4       Glycosylation 
1.4.1    Biosynthesis and structure 
Glycosylation is an extensive post-translational modification that can alter the 
function of proteins and thus the characteristics of the cell.  There are two main classes 
of glycosylation which are N- and O-glycosylation.  N-glycosylation involves the 
binding of N-acetylglucosamine to the amine side chain of asparagines, with sequence 
Asn-X-Ser(Thr), where X can be any amino acid except proline.  On the other hand, O-
glycosylation involves the binding of N-acetylgalactosamine to the hydroxyl of serine or 
threonine residue.  Glycosylation is protein core specific, species specific and tissue 
specific.  Thus, its activity is mainly controlled by a group of enzymes called 
glycosyltransferase.  The glycosyltransferases are classified based on their substrates 
and the basis of the structures they recognize as an acceptor.  The glycosyltransferases 
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catalyze the transfer of a sugar residue from a nucleotide to the particular biomolecules 
(protein or lipid) (Peracaula et al.,  2008). 
 
O- and N-glycosylation occur through several discrete steps that incorporate 
sugars using a glycosyltransferase.  For N-glycosylation, it is initiated by an 
oligosaccharide that comprise two N-acetylglucosamine, nine mannose and three 
glucose residues in the rough endoplasmic reticulum.  This 14 carbohydrate residues 
precursor is carried by a dolichol pyrophosphate, followed by the transfer of the 
oligosaccharide to an asparagine residue of the polypeptide chain.  Three glucose 
residues and one mannose residue are then removed by a specific glycosidase and 
consequently gives rise to three major classes of N-linked oligosaccharide: high 
mannose oligosaccharide, hybrid oligosaccharide and complex oligosaccharide by 
several enzymatic sequential pathways (Figure 1.1) (Ghazarian et al., 2011).  The high 
mannose oligosaccharide contains branches with two to six additional mannoses linked 
to the pentasaccharide core.  The hybrid oligosaccride consists of one complex branch 
and one or more high mannose branches while the complex oligosaccharide contains 
two or more branches with each of them consisting of at least one N-
acetylgalactosamine, one galactose and one sialic acid to form bi-, tri- or tetraantennary 
structures (Durand and Seta 2000). 
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Figure 1.1: Three different structures of N-linked oligosaccharides  
 
* Image was reproduced with permission from www.crystbbk.ac.uk 
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In case of O-glycosylation, N-acetylgalactosamine is covalently linked to the 
serine or threonine of a polypeptide chain.  This structure forms the Tn antigen if further 
elongation does not occur.  However, the elongation with galactose linked to the O-3 
position creates the core 1 structure, which is also known as the Thomsen-Friedenreich 
epitope.  The core 2 and 3 structures are formed with the covalently β1,6 or β1,3-linked 
of N-acetylglucosamine to N-acetylgalactosamine (Figure 1.2) (Dall’olio 1996).  These 
core structures can be further elongated by the addition of other carbohydrates such as 
galactose, fucose and N-acetylglucosamine to form a stable O-linked glycan (Durand 
and Seta, 2000).   The sialyl-Tn antigen is created by addition of sialic acid at the O-6 
position of the N-acetylgalactosamine residue (Dall’olio 1996). 
 
1.4.2    Glycosylation and its correlation to cancers 
Glycosylation plays many important roles in order to control the stability and the 
function of the cell.  It helps to maintain the homeostasis of the cell by being involved 
in processes such as being cell cycle regulators, anti-apoptotic proteins, transcription 
factors and tumor suppressors.  Furthermore, it stabilizes proteins for their proper 
folding, orientation and conformation.  Lastly, glycosylation also functions as signaling 
molecules, recognition molecules and adhesion molecules (Hakomori, 1985).  
 
Because of its enormous biological functions, aberrant glycosylation of 
glycoproteins is one of the most frequent changes that occurred in the cancer biological 
system.  The importance of the phenomenon is to provide better survival condition for 
cancer cell invasion.  Changes of glycosylation are usually related to three main types of 
patterns including, the synthesis of highly branched and heavily sialylated glycans, the 
expression of incomplete forms and the re-expression of glycosidic antigens of the fetal  
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Figure 1.2: Common core structures of O-linked oligosaccarides 
 
Abbreviations:  
GalNAc=N-acetylgalactosamine; 
β1,3Gal-T=β1,3-galactosyltransferase; 
 β1,6GlcNAc-T=β1,6-N-acetylglucosaminyltransferase; 
β1,3GlcNAc-T=β1,3-N-acetylglucosaminyltransferase;  
α2,6SA-T=α2,6-sialytransferase 
Image were reproduced with permission from Dall’olio 1996. 
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type (Dall’olio, 1996).  Aberrant glycosylation is more likely caused by the altered 
regulation of one or more key glycosyltransferase in the biosysnthesis of glycoproteins.  
For example, the GnT-III and GnT-V enzymes have their increased of activity in the 
formation of β1,6-branched Asp-linked oligosaccharides in hepatocellular carcinoma 
(Dennis et al., 1987; Fernandes et al., 1991).  This structure has been previously 
reported to correlate with the cancer progression.  Another example is the  
overexpression of GlcNAc-TV enzyme for the biosynthesis of β1,6-GlcNAc-branched, 
which has been shown to induce the metastatic potential of carcinoma cells of patients 
with breast cancer (Dennis et al.,  1999).  
 
 1.5      Gynaecological cancer 
Cancer is a group of cells that divides uncontrollably due to deactivation of 
programmatic death process and has the capability to spread to another part of the body 
through the blood system.  It becomes the most prevalent disease in the world and the 
leading cause of death.  According to the prediction of the International Agency for 
Research on Cancer (IARC), 27 million newly diagnosed cancer cases and 17 million 
cancer deaths will occur each year by 2030.  In fact, statistics of the worldwide cancer 
incident is frightening as a total of 12.7 million new cancer cases and 7.6 million cancer 
deaths have been reported in 2008 (Ferlay et al.,  2010).   
 
Gynaecological cancer refers to those malignant cancer cells that affect the 
organs and originated from the female reproductive organ, which include endometrium, 
cervix, ovary, vagina and vulvar.  Figure 1.3 shows the female reproductive organ.   
Endometrial, cervical and ovarian cancers are listed in the ten most common cancers 
affecting women worldwide (Table 1.2). 
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Figure 1.3: Female reproductive organ 
 
*Image was reproduced with permission from http://reproductivesysteminfo.com 
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Table 1.2: World ten most common cancer in women (Ferlay et al., 2010)  
Type of cancer              Number           Percentage         ASR 
                                       (‘000)                    (%)          (per100,000) 
Breast 1383 22.9 39.0 
Colon 
570 9.4 14.6 
Cervix 529 8.8 15.2 
Lung 513 8.5 13.5 
Stomach 349 5.8 9.1 
Endometrial 287 4.8 8.2 
Ovary 225 3.7 6.3 
Liver 225 3.7 6.0 
Thyroid 163 2.7 4.7 
Non-Hodgkin 
lymphoma 
156 2.6 4.2 
  ASR: Age standardized indices 
 
1.5.1    Endometrial cancer (ECa) 
1.5.1.1 Epidemiology 
According to IARC GLOBOCAN 2008, endometrial cancer (ECa) is the 6
th
 
most common cancer among women worldwide.  There were a total of 287,000 new 
cases that had been reported in 2008, which constituted 4.8% of the total case of women 
cancer.  The age standardized indices (Zareian, Khajeh et al.) were 8.2 per 100,000 
population for females, with a total of 74,000 death cases reported.  The incidence of 
ECa is highest in the developed region, with 50% of the total cases reported from this 
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region.  ECa has afavourable prognosis with a five year survival rate of approximately 
80-90% in the developed countries and 70% in the developing countries. 
 
In the year 2006, ECa was the 7
th
 most frequent cancer among women in 
Peninsular Malaysia (Omar et al., 2006).  It constituted 3.2% of the total female cancer 
cases which was equivalent to 372 cases registered under the Malaysian Cancer 
Statistics. The ASR was 4.4 per 100,000 population for female.  The incidence rate for 
ECa was highest among the Malaysian Chinese population (5.2 per 100,000 
population), followed by Malaysian Indians (4.7 per 100,000 population) and the 
Malays (2.8 per 100,000 population).  Its incidence rate increased with age after 30 
years old and achieved its peak at the age groups of 60-69 years old.   
 
1.5.1.2 Pathological classification 
ECa originates from glandular tissue within the inner lining of the uterus.  It is a 
heterogenous disease and therefore can be distinguished into two biologically different 
subtypes based on their clinical features and pathological appearance.  Type I ECa is 
associated with endometrial hyperplasia and grouped as endometrioid carcinomas.  It is 
the most common type of endometrial cancer which develops from endometrioid cells 
that form glands in the lining of the uterus (Sherman et al., 1995).  Type II ECa 
develops from a surface lesion and is a type of endometrial intraepithelial carcinoma 
called as serous carcinoma.  It is poorly differentiated, occurs spontaneously in 
postmenopausal women and more aggressive in tumour invasion (Purdie, 2003).  
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1.5.1.3 Etiology  
The precise cause of ECa remains unknown, even though several risk factors 
have been determined.  ECa is known to be related to an increase in the levels of 
estrogen and obesity (Kaaks et al., 2002).  Therefore, women who have never been 
pregnant, undergone early puberty or late menopause and exposed to high level of 
estrogen are more likely to contract ECa.  Exposure to tamoxifen has also been reported 
to be associated with high rates of ECa. Tamoxifen is a drug which has properties 
similar to estrogen and is prescribed for the prevention or treatment of breast cancer.  In 
addition, a diet with a high intake of animal fats also increases the risk of ECa.  Women 
with a history of breast, ovarian and colon cancer or have a family history of ECa are 
also at high risk (Schoen et al., 1994).  Lynch Syndrome, which is also known as 
hereditary nonpolyposis colorectal cancer syndrome, can increase the risk through the 
inheritance of genetic mutation associated with ovarian and colon cancer (Bewtra et al., 
1992).  However,  the correlation of breast cancer and ECa remained obscure.  
 
1.5.1.4 Staging 
The surgical staging of ECa was first introduced by the Federation of 
International Gynecologists and Obstetricians (FIGO) in 1988.  Recently, the FIGO 
staging system for endometrial cancer was revised as shown in Table 1.3 (Creasman, 
2009).  
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Table 1.3: FIGO Staging of ECa (Creasman, 2009) 
    Stage                                         Description  
       IA Tumor confined to uterus, <50% myometrial invasion 
IB Tumor confined to uterus, ≥50% myometrial invasion 
II Cervical stromal invasion 
IIIA Tumor invasion into serosa or adnexa 
IIIB Vaginal or parametrial involvement 
IIIC1 Pelvic node involvement 
IIIC2 Paraaortic node involvement 
IVA Tumor invasion into bladder or bowel mucosa 
IVB Distant metastases (including abdominal metastases) or inguinal  
lymph node involvement 
 
 
1.5.1.5 Screening and diagnosis 
Currently, the diagnosis of ECa is very dependent on endometrial biopsy, which 
involves suction of the uterine wall tissue for endometrial histology evaluation.  
However, it is invasive, highly subjective and not adequately sensitive and specific  for 
the routine diagnosis of ECa.  Another method for the diagnosis of ECa is transvaginal 
ultrasound.  Through the ultrasound imaging, the thickness and abnormalities of the 
endometrial cells can be detected with good sensitivity (Jacobs et al., 2011).  The most 
advanced detection method for ECa is magnetic resonance imaging, which can 
accurately assess the histology staging of the cancer and tumor response to therapy and 
differentiate tumor recurrence from post-treatment changes (Beddy et al.,  2012).  Up 
until now, no tumor marker has been established specifically for ECa, even though 
several serum markers such as CA125 , CA19-9, CA15-3, CA72-4 and CEA that are 
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known to be non-specific are currently being applied for its diagnosis (Ueda et al., 
2010).    
 
1.5.2    Ovarian Cancer (OCa) 
1.5.2.1 Epidemiology 
Ovarian cancer (OCa) is the 7
th
 most common cancer in women, with a total of 
225000 new cases reported in 2008 (Ferlay et al.,  2010).  Although OCa is the third 
most common gynaecolgical cancer after ECa and CCa, it is the most fatal malignancy 
due to its late presentation of symptoms, weak response to treatment and high 
recurrence rate.  Approximately 140,000 deaths or 4.2% of all women cancer death rates 
are due to this cancer.  The incidence rate of OCa is higher in the developed region 
compared to the developing region.  The ASR for developed and developing regions 
were 9.4 and 5.0 per 100,000 populations, respectively.   
 
OCa is the fourth most common cancer for female in Malaysia (Lim and Yahya, 
2003).  In the year 2007,  there were 658 women in the Peninsular Malaysia who were 
diagnosed with OCa.  The incidence of OCa in Peninsular Malaysia increased with age 
with the ASR of 7.6 per 100,000 population.  Among the three major races of 
Malaysians in the peninsular, the Malay women had the highest incidence rate for OCa 
with the ASR of 6.8 per 100,000 population.  This is followed by the Malaysian Indians 
(6.4 per 100,000 population) and Chinese (5.8 per 100,000 population).  
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1.5.2.2 Pathological Classification 
OCa is also a heterogenous malignancy that develops from diverse types of cells 
within the ovary.  According to FIGO, OCa is classified into three main types, which 
are the epithelial tumour, the germ cell tumour and the sex cord stroma tumour (Brown, 
2001).  Epithelial tumour arises from the germinal epithelium lining of the ovary.  It 
constitutes approximately 85% of all malignant ovarian tumours.  It is further 
subdivided into several subtypes, including serous, mucinous, endometroid, clear cell, 
transitional cell, mixed and undifferentiated carcinoma.  Around 10-20% of the 
epithelial tumours have low malignant potential, which is called borderline ovarian 
carcinoma.  It is a histologic variant that is less aggressive without stromal invasion but 
only demonstrates papillary proliferation and multilayering of epithelial cells with 
nuclear abnormalities (Soslow, 2008). 
 
Germ cell tumour accounts for 5% of all OCa and develops in the embryo or 
placenta structures.  It usually occurs in women younger than 30 years old.  The most 
common type of germ cell tumour is called dysgerminoma, which consists of glycogen-
rich cells that resemble germinal epithelium in a stroma with lymphoid cells (Young et 
al., 1994).  Other less common histologic subtypes include endodermal sinus tumor, 
immature teratoma, choriocarcinoma and embryonal carcinoma.  
 
Sex cord stromal tumour constitutes 5% of all OCa.  It mainly develops in the 
connective tissues and supporting ovarian stroma.  This tumour is generally less 
aggressive and usually secretes steroid hormones, such as estrogen and androgen (Reed 
et al., 2010). 
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1.5.2.3 Etiology 
One of the main causes of OCa is the accumulation of genetic mutations.  About 
10% of OCa cases are predominantly caused by mutations in the BRCA1 and BRCA2 
genes which is known as breast-ovarian cancer syndrome (Gevensleben et al., 2010).  
Both the BRCA1 and BRCA2 are tumour suppressor genes, which are important in the 
regulation of the cell growth and proliferation.  Therefore, the loss of functions for both 
genes have led to further mutations and genomic instability followed by the initiation of 
carcinogenesis (Pradhan et al., 2010).  The primary function of the BRCA genes is to 
preserve the structural and numerical stability of chromosomes during cell division.  
The BRCA1 expression proteins are responsible for repair of the double strand DNA 
breaks with error free homologus recombination.  On the other hand, BRCA2 functions 
as mediator of interaction for homologus recombination.   
 
The second type of inherited genetic mutations associated with OCa is the 
hereditary nonpolyposis colorectal cancer or Lynch syndrome.  Patients with this 
syndrome are at an increase risk with cancers of gastrointestinal tract organs, upper 
urological tract and female genital organs including the ovary and endometrium 
(Watson and Lynch, 1993).  Lynch syndrome is associated with mutations in the 
mismatch repair genes located within the DNA mismatch repair pathway (Lu, 2008).  
This eventually affects the stability of the genome and the function of the tumour 
suppressor genes. 
 
The development of ovarian malignancy which also refers as sporadic ovarian 
cancer has been identified to be correlated to genetic alteration in a complex pathway 
involving multiple oncogenes and tumour suppressor genes, including p53, p16, p27, 
HER2/neu, fms, ras, c-myc, myb, BRAF, KRAS, PTEN and  M-CSF (Gallion et al.,  
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1995).  They are altered in expression or in their various mechanisms such as gene 
amplification, point mutation and chromosomal translocation (Kacinski et al., 1990; 
Gallion et al., 1995; Shih Ie and Kurman, 2004). 
 
Besides genetic factors, both the endogenous factors, including age, family 
history with ovarian, breast, cervical or colon cancer, infertility, early puberty, late 
menopause and hormone, as well as the exogenous factors, including environmental 
factors, diet, lifestyle and biological and chemical exposure have also been reported to 
increase the risk of OCa (Booth et al., 1989; Daly and Obrams, 1998).  However, the 
risk of OCa is reduced when a woman has her pregnancy at an early age, early 
menopause and used oral contraceptives (Booth  et al.,  1989). 
 
1.5.2.4 Staging 
The current staging for OCa is the FIGO system developed in 1987.  It is based 
on evaluations obtained from the surgical exploration of ovarian tissues and its 
surrounding.  Table 1.4  shows the FIGO staging of OCa. 
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Table 1.4: FIGO staging of OCa (FIGO, 1987) 
    Stage                                         Description  
       I Growth limited to ovaries only 
      IA One ovary involved with intact capsule and no tumor on external 
surface 
      IB Both ovaries involved with intact capsule and no tumor on external 
surface 
      IC One or both ovaries with tumor on surface and capsule ruptured  
      II Pelvic extension  
      IIA  Metastasis to uterus and/or fallopian tubes 
      IIB Metastasis to other pelvic tissues 
      IIC Metastasis to uterus, fallopian and pelvic tissues with tumor on 
surface or capsule ruptured 
      III Tumor involved one or both ovaries with peritoneal implants 
outside the pelvis and/or positive retroperitoneal or inguinal nodes 
      IIIA Tumor limited to the true pelvis with negative nodes but 
histologically confirmed microscopic seeding of abdominal 
peritoneal surfaces 
      IIIB Tumor involved one or both ovaries, histologically confirmed 
implants on abdominal peritoneal surfaces <2cm 
      IIIC Abdominal implants >2cm and/or positive retroperitoneal or 
inguinal nodes 
      IV Growth involved one or both ovaries with distant metastasis 
 
 
1.5.2.5 Screening and diagnosis 
Currently, pelvic examination, transvaginal ultrasound screening of the ovary 
and tumor marker panels such as CA125 detection are used to screen and diagnose OCa.  
The application of pelvic examination is still not well established due to its low 
sensitivity and specificity for detection of the cancer.   Transvaginal ultrasound with or 
without power Doppler is used to identify abnormalities of the ovary and is capable to 
Introduction 
33 
 
distinguish benign ovary and malignant masses of OCa.  It is highly sensitive but is not 
cost effective and has an unsatisfactory specificity (Menon, 2004).  CA125 is 
recognized by FIGO as one of the approved tumour markers for OCa.  The level of 
CA125 is elevated for approximately 90% of patients with advanced OCa but only 50% 
of patients with early stage of OCa (Gupta and Lis, 2009).  In addition, the CA125 has 
limited specificity in detecting OCa as it is also raised in other types of cancers and 
gynecologic or non-gynaecologic conditions as well.  Although the combination of 
CA125 and transvaginal ultrasound can improve the sensitivity and specificity for early 
detection of OCa, many cases of OCa are only detected at the advance stages of the 
cancer, which are associated with high rates of mortality.  
 
1.5.3    Cervical Cancer (CCa) 
1.5.3.1 Epidemiology 
CCa is the second most frequent cancer affecting women worldwide (Ferlay et 
al.,  2010).  In 2008, approximately 529,000 women were newly diagnosed with CCa, 
which constituted roughly 8.8% of all female cancers.  The mortality rate was 0.52 with 
a total of 275,000 patients died caused by CCa.  Indeed, it is considered as a leading 
cause of death for women in the developing countries, which accounts for about 88% of 
cancer death that occurred in the region.  The incidence rate of CCa was the highest in 
the developing region, particularly Africa, South America and South Central Asia. 
 
In Malaysia, CCa is ranked the third most common cancer after breast cancer 
and colorectal cancer among women.  But in Peninsular Malaysia, it was the fourth 
most frequent cancers, constituting 4.9% of the total cancer cases registered with the 
National Cancer Registry in the year 2006 (Omar et al., 2006).  Current estimates 
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indicate that approximately 1,492 Malaysian women are detected with CCa every year.  
More than half of the women were diagnosed at an advanced stage and 766 die from the 
disease.  The Social Statistic Bulletin of Malaysia 2005 reported that the death rate for 
CCa was rising from 0.29% in 1996 to 0.41% in 2000 (Abdullah and Su, 2010).  The 
overall ASR was 12.2 per 100,000 population.  CCa commonly affected  females with 
ages more than 30 years and had its peak at the age group of 60-69 years.  The 
Malaysian Chinese women had the highest ASR, which was 13.6 per 100,000 
population.  This was followed by the Malaysian Indians (11.3 per 100,000 population) 
and the Malays (7.3 per 100,000 population). 
 
1.5.3.2 Pathological classification 
            CCa originates at the squamocolumnar junction in the cervix.  It can be 
differentiated into two groups, which are squamous cell carcinoma and adenocarcinoma 
(Kaur et al., 2003).  Squamous cell carcinoma is the most common subtype of CCa, 
which accounts 85% of the total CCa’s incidence.  It arises from the surface lining of 
the ectocervix connected to the endocervix.  On the other hand, adenocarcinoma arises 
within glands located in the endocervix. 
 
1.5.3.3 Etiology 
Studies have shown that the human papillomavirus (HPV) infection is the main 
causative agent for more than 90% cases of invasive CCa worldwide (Franco et al., 
2001).  The HPV infection affects women who are sexually active and have weakened 
immune system.  HPV can be divided into two distinct categories, which are the low 
risk and high risk types.  The low risk type rarely cause development of CCa.  On the 
other hand, the high risk HPV including types 16, 18, 31 and 45 give rise to the high 
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grade cervical intraepithelial neoplasia, which is a precursor of invasive CCa.  HPV-
induced cancers express two viral oncoproteins E6 and E7, which interact with p53 and 
the tumor suppressor gene product pRb, respectively.  This ultimately induces genetic 
instability and thus leads to carcinogenesis of the cervical cells by activation and 
inactivation of the tumour suppressor genes (Senba and Mori, 2012). 
 
1.5.3.4 Staging 
The classification of CCa is mainly based on clinical evaluation of the cervix 
lesions.  Table 1.5 shows the revised FIGO staging system for CCa that is currently 
being used.   
 
1.5.3.5 Screening and diagnosis 
Screening of CCa is currently performed by the Papinicolaou (Pap) smear 
method.  Pap smear, which was introduced in Malaysia 30 years ago, detects cytologic 
abnormalities of lesions collected from the end of the uterus extending into the vagina. 
However, the popularity of this method is still unsatisfactory among Malaysian women.    
 
According to a report from the National Health and Morbidity Survey 1996, only 
26% of Malaysian women have been covered by this method (Wong et al., 2009).  To 
date, it is still the most important and useful tool for prevention of CCa.  Yet, it is highly 
subjective and has low sensitivity and specificity (Boulet  et al., 2008).  
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Table 1.5: FIGO staging of CCa (Odicino et al., 2008) 
    Stage                                         Description  
      IA Invasive carcinoma diagnosed only by microscopy. All 
microscopically visible lesions even with superficial invasion are 
stage IB. 
      IA1 Stromal invasion no greater than 3.0 mm in dept and 7.0 mm or 
less in horizontal spread.  
      IA2 Stromal invasion greater than 3.0 mm and not more than 5.0 mm 
with a horizontal spread of 7.0 mm or less.  
      IB Clinically visible lesion confined to the cervix or microscopic 
lesion greater than IA2. 
      IB1 Clinically visible lesion 4.0 cm or less in greater dimensions. 
      IB2 Clinically visible lesion more than 4.0 cm in dimension.  
      II Tumor invades beyond the uterus but not to the pelvic wall or to 
lower third of the vagina. 
      IIA Without parametrial invasion. 
      IIB With parametrial invasion. 
      III Tumor extends to pelvic wall and/or involves lower third of vaginal 
or causes hydronephrosis or non-functioning kidney. 
      IIIA Tumor involves lower third of vagina, no extension to pelvic wall. 
      IIIB Tumor extends to pelvic wall and/or causes hydronephrosis or non-
functioning kidney. 
      IVA Tumor invades mucosa of bladder or rectum and/or extends beyond 
the true pelvic. 
      IVB Distant metastasis 
 
 
As mentioned earlier, HPV is responsible for the carcinogenesis of CCa.  
Therefore, it has been suggested that HPV testing can improve the efficiency of CCa 
screening.  Currently, there are two types of detection technologies for HPV screening, 
which are Hybrid capture 2 and PreTect HPV-Proofer (Keegan et al., 2009).  Hybrid 
capture 2 is a signal amplified hybridization microplate-based assay used to detect 18 
types of high and low risk HPV types using probe cocktails (Poljak et al., 2002).  It was 
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recognized and approved by FDA in 2003 as a primary screening test for CCa as it 
provides sufficient scientific evidences to support its performance in clinical 
diagnostics.  On the other hand, PreTect HPV-Proofer is a real-time based multiplex 
NASBA used to detect the HPV type specific E6/E7 mRNA from the HPV high risk 
types 16, 18, 31, 33 and 45 (Molden et al.,  2007).  Compared with the Hybrid capture 
2, it is more specific in identifying women with high grade cervical intraepithelial 
neoplasia 2+ but has a lower sensitivity (Ratnam et al., 2010). Recently, a novel method 
known as MassARRAY spectrometry utilizes competitive PCR, primer extension and 
MALDI-TOF/TOF to detect 15 types of high risk HPV (Basu et al., 2011).  However, 
this method is still under assessment for clinical application. 
 
Another approach for the diagnosis of CCa is the utilization of serum 
biomarkers.  The squamous cell carcinoma antigen is the most commonly used serum 
marker for squamous cell cervical carcinoma, followed by the serum fragment of 
cytokeratin 19 (CYFRA 21-1).  Pre-treatment serum levels of both markers have been 
demonstrated to be correlated with the disease stage, tumor size, depth of the stromal 
invasion, the lymph-vascular space involvement and lymph node metastasis (Ueda et 
al.,  2010).  Similarly, carcinoembryonic antigen (CA), CA 125, CA 19-9 have been 
used to detect the adenocarcinoma even though they have inadequate positive rates 
toward to the disease (Ueda et al., 2010).  In general, the use of specific markers for 
CCa  in conjunction with Pap smear and HPV testing can improve the accuracy, 
precision and sensitivity of the screening program for CCa.   
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1.6 Problem statement and rationale of the study 
 The diagnosis of ECa, OCa and CCa currently relies on existing tumor markers 
that are not adequately sensitive and specific for early detection of the cancers.  In view 
of these limitations, there is a need to identify new biomarkers that are more specific 
and sensitive to assist in the early and accurate identification of the cancer patients, 
which may improve the rates of mortality of the cancers.  Urine of the patients may 
contain aberrant proteins that can be used as new biomarkers.  Urinary biomarkers, if 
identified, provide the advantage of performing the diagnosis non-invasively.  
 
1.7       Research objectives 
The aim of the present study was to analyze urinary proteins from patients with 
gynecological cancers, including ECa, OCa and CCa, for abnormally glycosylated or 
excreted glycoproteins using the champedak lectins as probes.  The aberrantly 
glycosylated or expressed urinary proteins that were recognized by the lectins are 
potential biomarkers that may be used in the screening detection and/or monitoring of 
the cancers.   
           The specific objectives of the study were: 
1) To develop 2-DE profiles of urinary proteins from control and patients with 
ECa. 
2) To compare 2-DE profiles of urinary proteins from control and patients with 
ECa using Image Master 2D Platinum software. 
3) To generate proteome maps of urinary N- and O-glycosylated proteins using 
western blotting cum lectin approach, lectin affinity chromatography, LC-
MS/MS analysis and SELDI-TOF profiling. 
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4) To compare the glycoprotein maps of healthy control individuals with those 
generated from women with ECa, OCa and CCa.  
5) To identify the abnormally gylcosylated or expressed glycoproteins that have 
the potential to be used as cancer biomarkers.   
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CHAPTER 2:  MATERIALS AND METHODS 
 
2.1  Materials 
2.1.1 Urine sample 
 
Approximately fifty ml of morning midstream urine samples were obtained from 
patients who were newly confirmed with stage IB and IIA/B gynaecological cancers, 
ECa (n=7), OCa (n=9) and CCa (n=8), prior to treatment or surgery in the morning at 
the Gynaecology Clinic, University of Malaya Medical Centre, Kuala Lumpur.  All 
patients were confirmed with negative diagnosis for other diseases and showed normal 
serum creatinine values.  Control urine samples (n=11) were obtained from normal 
healthy volunteers with the same range of age (30 years old to 75 years old).  Samples 
were collected with subjects’ consents and approval (MEC. REF.NO.: 435.18) granted 
by the Ethical Committee (Institutional Review Board) of the Medical Centre and the 
Medical Research and Ethics Committee of the Ministry of Health, Malaysia, in 
accordance to the ICH GCP guideline and the Declaration of Helsinki.  The urine 
samples were preserved by adding sodium azide to a final concentration of 20 mM prior 
to centrifugation at 10000 × g for 15 minutes at 4
o
C.  The samples were dialyzed against 
four changes of 2 L of distilled water for 12 hours at 4
o
C before being aliquoted, freeze-
dried and stored at -80
o
C.  
 
2.1.2  Champedak (Artocarpus integer) 
           Two champedak fruits that were used to isolate one batch of CGB and CMB 
lectins were obtained from a fruit orchard in Kota Bahru, Kelantan.   
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2.1.3  General materials  
           The materials used during the course of this project and their respective brands 
and suppliers are as listed.  All chemicals were of analytical grade and were purchased 
from Sigma Aldrich Company, St. Louis, U.S.A. unless stated. 
 
Enzymes and substrates 
1. Roche Molecular Biochemicals, Mannheim, Germany 
Activated alkaline phosphatase (AP) 
NBT/BCIP tablets 
2. Promega, Madison, USA 
Trypsin Gold, mass spectrometry grade 
 
Chromatographic materials 
1. GE Healthcare Biosciences, Uppsala, Sweden 
Preactivated CNBr Sepharose 4B 
 
Two-dimensional electrophoresis 
1. GE Healthcare Biosciences, Uppsala, Sweden 
IEF immobiline dry strips 11 cm (pH 3-10) 
IPG buffer (pH 3-10) 
Drystrip cover fluid 
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2. BioRad Laboratories Inc., U.S.A. 
Pre-stained broad range SDS-PAGE standard 
 
SELDI Biochemical Arrays and matrices 
1. BioRad Laboratories Inc., U.S.A. 
ProteinChip® array PS10 
α-cyano-4-hydroxycinnamic acid (CHCA) 
 
Commercial kits 
1. Pierce, Rockford Illinois, U.S.A. 
BSA Protein assay kit 
Metal enhanced DAB solution kit 
 
2.1.4  Standard solutions 
Phosphate-buffered saline (PBS) 
(170 mM NaCl, 3.4 mM KCl, 10.0 mM Na2HPO4,  1.8 mM KH2HPO4, pH 7.2) 
NaCl                                                            9.36 g 
           KCl                                                                0.25 g 
           Na2HPO4                                                          0.25 g 
           KH2HPO4                                                       1.42 g 
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The solution was made up to 1 L with distilled water and pH was adjusted to pH 7.2. 
The solution was stored at room temperature.  
 
Tris Buffered Saline (TBS)  
(100 mM Tris-HCl, 0.9% NaCl) 
     Tris                                                             12.11 g 
          NaCl                                                         9.00 g 
Tris was dissolved in 900 ml distilled water and the pH of the solution was adjusted to 
7.5 by addition of concentrated HCl.  NaCl was then added and the solution was made 
up to 1 L with distilled water. 
 
2.2  Methods 
 In the present study, the urine samples of control and patients with ECa, OCa 
and CCa were analyzed using three approaches, which include 2-dimensional 
electrophoresis-lectin based Western blotting, lectin affinity chromatography-liquid 
chromatography and SELDI-TOF.  Figure 2.1 shows the overall flow of methodology 
used in this study.         
 
2.2.1  Purification of champedak lectins 
2.2.1.1 Extraction of crude lectin from champedak seeds 
           The seeds of champedak were peeled, cleaned with distilled water and dried at 
room temperature.  The dried seeds were ground to powder with a blender.  Forty grams  
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Figure 2.1: The overall flow of methodology adopted in the present study. 
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of the powdered seed were suspended in 400 ml of PBS pH 7.4 and stirred for 24 hours 
at 4
o
C.  The homogenate was centrifuged at 8000 × g for 15 minutes at 4
o
C.  
Supernatant was collected and subjected to 60% ammonium sulphate precipitation and 
stirred for 2 hours at 4
o
C.  The solution was then centrifuged at 8000 × g for 15 minutes 
at 4
o
C.  The resulting pellet was collected and dissolved in cold PBS.  Four times 
extensive dialysis of dissolved pellet was done in 48 hours.  Finally, the crude extract 
was aliquoted and kept at -20
 o
C. 
 
2.2.1.2  Preparation of Galactose and Mannose Sepharose-4B columns  
Activation of Sepharose-4B with Divinylsulfone 
           Divinylsulfone (DVS) introduces reactive vinyl groups in Sepharose, which 
reacts with hydroxyl groups of sugar, causing covalently immobilization of sugars on 
Sepharose.  A hundred ml of Sepharose-4B was washed with 1 L of distilled water in a 
sintered glass funnel, suctioned to a wet cake and transferred to a 500 ml beaker. The 
moist gel was suspended in 100 ml of 0.5 M sodium carbonate and stirred slowly in a 
fume cabinet.  Ten ml of DVS was added slowly to the suspension over a period of 15 
minutes in a fume cabinet with constant stirring.  The gel was then stirred for 1 hour at 
room temperature before it was washed extensively with 1 L of distilled water until the 
filtrate was no longer acidic.  The activated Sepharose was ready for ligand coupling. 
 
Coupling of sugar to DVS-activated Sepharose-4B 
           Isolation of CGB lectin and CMB lectin were performed using immobilized 
galactose and mannose columns, respectively.  Twenty ml of DVS activated gel was 
suspended in an equal volume of 20% (w/v) of D-galactose or D-mannose in 0.5 M 
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sodium carbonate.  The mixture was stirred for 24 hours at room temperature.  The gel 
was then washed with 2 L of water and 2 L of 0.5 M sodium bicarbonate. The gel was 
resuspended in 0.5 M sodium bicarbonate containing 2 ml of β-mercaptoethanol and 
stirred for 2 hours in a fume cabinet at room temperature.  The gel was later washed 
with 2 L of distilled water, followed with 2 L of PBS.  The resulting galactose-coupled 
and mannose-coupled Sepharose-4B gels were packed respectively into 2.8 cm diameter 
polypropylene columns of 5 cm in height. 
 
2.2.2  Purification CGB and CMB lectins 
2.2.2.1 Isolation of CGB lectin 
           Prior to isolation of the CGB lectin, the galactose column was pre-equilibrated 
with PBS.  Twenty ml of crude extract of champedak seeds was applied into the column 
and washed with PBS.  Unbound fractions of 10 ml each were collected and absorbance 
was monitored at 280 nm.  Peak fractions with absorbance more than 0.4 were pooled 
and kept for CMB lectin affinity isolation.  The bound fractions containing CGB lectin 
were eluted using 1 ml of 0.8 M galactose in PBS, pH 7.4.  The bound fractions with 
high absorbance more than 0.4 were pooled and dialysed against four times changes of 
PBS for 12 hours each.  The dialysed bound fractions were freeze-dried, prior to storage 
at -20
o
C.  
 
2.2.2.2 Isolation of CMB lectin 
           Isolation of the CMB lectin was performed using the unbound fraction collected 
from the previously mentioned CGB lectin isolation procedure.  The fraction was 
loaded into a mannose column and loading and elution of the column was performed 
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using the same procedure that was described for the CGB lectin.  A solution of 0.8 M 
D-mannose in PBS, pH 7.4 was used to elute the bound fraction containing the CMB-
lectin.  The dialysed bound fractions were freeze-dried, prior to storage at -20
o
C.  After 
elution of the desired lectins, both the galactose and mannose columns were regenerated 
by washing extensively with PBS before being reused. 
 
2.2.2.3 Preparation of cellulose membrane for dialysis 
           Cellulose membrane tubings were incubated in hot distilled water for three hours 
to remove glycerin, prior to use.  The tubings were then treated with 0.3% (w/v) sodium 
sulfide to remove sulfur compounds at 80
o
C for a minute and immediately washed with 
60
o
C distilled water for 2 minutes.  The tubings were then acidified with 0.2% (v/v) of 
sulfuric acid for one minute and finally rinsed with hot water for another one minute 
before ready to be used.  
 
2.2.3  Assessment of purified CGB and CMB lectins. 
2.2.3.1 Determination of the concentrations of CGB  and CMB lectins.  
           Concentrations of the isolated lectins were estimated using a commercial protein 
assay kit based on the method of Bradford from Pierce, Illinois.  The concentration 
estimation was performed according to the manufacturer’s instruction.  Bovine serum 
albumin (BSA) at 2 mg/ml was used as standard.     
 
2.2.3.2 Assessment of the purity of CGB and CMB lectins using SDS-PAGE 
           The purity of isolated lectins were evaluated by SDS-PAGE. The gel was 
stained with Coomassie Blue to obtain the protein profiles of the lectins.  
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Standard solution for SDS-PAGE 
All solutions were stored at 4
o
C, unless stated. 
Solution A: 30% acrylamide, 0.8% N,N-methylenebisacrylamide 
            Acrylamide                                                    60 g 
           N,N-methylenebisacrylamide                        1.8 g 
           Distilled water                                               topped up to 200 ml 
The solution was then stored in a dark bottle. 
 
Solution B: 1.5 M Tris-HCl, pH 8.8 
   Tris base                                                          36.23 g 
         Distilled water                                                 150 ml 
pH of the solution was adjusted to 8.8 using HCl and topped up to 200 ml. 
 
Solution C: 10% (w/v) SDS  
           SDS                                                                   10 g 
           Distilled water                                                  100 ml 
The solution was stored at room temperature. 
 
Solution D: 10% (w/v) Ammonium persulphate (APS) 
           APS                                                                   25 mg 
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           Distilled water                                                   0.25 ml 
APS solution was prepared fresh prior to the preparation of the gel. 
 
Solution E: N, N, N
, 
, N
, 
tetramethylethylenediamine (TEMED) 
 
Solution F: 0.5 M Tris-HCl, pH6.8 
           Tris base                                                              6.1 g 
           Distilled water                                                    50 ml 
The solution was adjusted to pH 6.8 using HCl and topped up to 100 ml. 
 
4X SDS-PAGE sample buffer:  
(62.5 mM Tris-HCl, pH 6.8, 10% (w/v) glycerol, 2% (w/v) SDS, 1% (w/v) DTT and 
0.01% (w/v) bromophenol blue) 
         0.5 M Tris-HCl, pH 6.8                                 2.5 ml 
         Glycerol                                                                2 ml 
          SDS                                                                  400 mg 
          DTT                                                                 200 mg 
          Bromophenol blue                                             20 mg 
All chemicals listed above were mixed and topped up to 20 ml with deionized distilled 
water. 
Electrophoresis Buffer:  
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(25 mM Tris base, 198 mM glycine, 0.1% (w/v) SDS) 
         Tris base                                                         1.22 g 
             Glycine                                                           5.94 g 
             SDS                                                                  0.4 g 
The solution was topped up to 1 L with distilled water. 
 
Fixing solution 
          10% (v/v) acetic acid                                            10 ml 
          40% (v/v) methanol                                             40 ml 
The solution was made up to 100 ml with distilled water. 
 
Hot Coomassie Blue stain 
          10% (v/v) acetic acid                                              10 ml 
          0.1% (w/v) Coomassie Brilliant Blue (R250)          0.1 g 
The chemicals were mixed and topped up to 100 ml. The staining solution was stored at 
room temperature and heated prior to use. 
 
Destaining solution  
          10% (v/v) acetic acid solution 
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2.2.3.3 Preparation of stacking and separating gels 
           Glass plates were assembled and checked for leakage with distilled water before 
a mixture of 18% separating gel was poured into the sandwich.  The mixture of 
separating gel was prepared according to the Table 2.1.  The gel was overlaid with a 
layer of distilled water to achieve an even gel surface.  Once the gel polymerized, the 
overlaid water was removed with a filter paper.  The stacking gel mixture was prepared 
as stated in Table 2.1.  It was layered on top of the separating gel and a gel comb was 
inserted into it before it was polymerized. 
 
Table 2.1: Volumes of stock solution used to prepare the separating and stacking 
gels of SDS-PAGE 
Stock Solution                     Volumes of stock solutions for 
      Separating gel (18%)      Stacking gel (4%) 
Solution A (ml)                     12.00                   0.65 
Solution B (ml)                       5.00                     - 
Solution C (µl)                    200.00                  50.00 
*Solution D (µl)                   100.00                  25.00 
*Solution E (µl)                       6.60                    5.00 
Solution F (ml)                        -                    1.25 
Distilled water (ml)                        2.69                    3.05 
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Total volume (ml)                      20.00                      5.03 
  *The solutions were added prior to use 
 
2.2.3.4 SDS polyacrylamide electrophoresis 
           Samples were mixed at a ratio of 3:1 with sample buffer in a microcentrifuge 
tube and boiled at 95
o
C for 5 minutes.  Ten µl of each samples and broad range 
molecular weight standard (Biorad Laboratories Inc., U.S.A.) were loaded into the 
wells. Electrophoresis was conducted at a constant voltage of 100 V and stopped once 
the blue front dye approached 1 cm from the gel bottom.  The gel was then stained with 
hot Coomassie staining protocol. 
 
2.2.3.5 Hot Coomassie staining protocol 
           The fixing solution was poured into a container containing the gel and fixed 
overnight on a shaker.  The Coomassie stain was heated up to 90
o
C in a microwave 
oven.  The fixing solution was poured out and replaced with the staining solution 
followed with 30 minutes shaking.  The staining solution was removed from the 
container and 20 ml of destaining solution was then added.  The gel was left to shake 
overnight before being rinsed with distilled water and scanned. 
 
2.2.4  Two-dimensional gel electrophoresis 
           Separation of the proteins using two-dimensional gel electrophoresis involves 
two steps.  For the first dimension, the proteins were separated based on their isoelectric 
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points (pI) and in the second dimension, separation of the electrofocused proteins was 
based on their molecular weights. 
 
2.2.4.1 First dimension electrophoresis 
Stock solution: 
Rehydration buffer  
(8 M urea, 2% NP40, 0.5% Pharmalyte, 0.002% Orange G) 
                Urea                                                         12 g 
                NP40                                                        120 µl 
                Pharmalyte                                               125 µl 
               1% Orange G                                               50 µl 
All chemicals were mixed, made up to 25 ml and stored in 2.5 ml aliquots at -20
o
C. 
 
2.2.4.2 Preparation of sample for rehydration  
           The concentration of the freeze dried sample was estimated based on the method 
as described in Section 2.2.3.1.  A tube of rehydration solution was thawed and 7 mg of 
DTT was added into the solution.  Three hundred µg protein was dissolved with 200 µl 
rehydration solution.  Each sample was analysed once.  The sample mixture was loaded 
into the slot of the reswelling tray. An 11 cm pH 3-10 linear IPG strip was put into the 
slot with the gel facing down on the sample mixture.  Drystrip cover fluid was pipetted 
to cover the whole slot and the strip. The IPG drystrips were left to reswell for 16 hours 
at room temperature. 
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2.2.4.3 Isoelectric focusing 
           The first dimension separation was conducted using IPGphor (GE Healthcare 
Biosciences, Uppsala, Sweden).  The temperature was set at 20
o
C throughout the whole 
experiment.  The rehydrated IPG strips were placed on the tray across the cathodic and 
anodic ends.  Moistened electrode strips were placed on both ends of the rehydrated IPG 
strips.  Both electrodes were put on both end of strip touching the moistened electrode 
strips.  The IPG strips were covered with Drystrip cover fluid to ensure good thermal 
contact. 
 
          The first dimension isoelectricfocusing was conducted according to the 
recommended protocol by the manufacturer as shown below. 
      Phase     Voltage         mA         W       V/hr 
          1         100           50          5        100 
          2        1000           50          5        1000 
          3        8000           50          5       12500 
 
Once the first dimension electrophoresis was completed, the focused strips were 
individually stored at -80
o
C in screw cap tubes and ready for the second dimension 
electrophoresis. 
 
2.2.4.4 Second dimension electrophoresis 
Stock solutions 
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SDS equilibration solution 
          4X resolving gel buffer                                       20 ml 
          Urea                                                                   144.14 g 
          Glycerol                                                              138 ml 
          SDS                                                                        8 g 
The solution was made up to 400 ml with distilled water. 
 
Electrophoresis buffer  
(25 mM Tris-HCl, pH 8.3, 192 mM glycine, 0.1% SDS) 
          Tris base                                                             3.03 g 
          Glycine                                                               14.4 g 
          SDS                                                                     1.0 g 
The solution was made up to 1L with distilled water.  
 
0.5% agarose sealing solution  
          Agarose                                                                0.5 g 
          Electrophoresis buffer                                         100 ml 
The mixture was heated in a microwave oven until the agarose was dissolved 
completely. 
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2.2.4.4.1 Preparation of 12.5% SDS PAGE gel 
           Glass plates were assembled as a sandwich in the gel caster according to the 
manufacturer’s manual.  A linear gel of 12.5% acrylamide was prepared according to 
the recipe in Table 2.2.  Solutions for casting of the gel are described in Section 2.2.3.3.  
The gel was overlaid with distilled water and allowed to polymerize. 
 
Table 2.2: Volumes of stock solutions for 12.5% gel 
   Volumes of stock solutions  
       Separating gel (12.5%) 
Solution A (ml)                     2.606 
Solution B (ml)                      1.563 
Solution C (µl)                     62.500 
*Solution D (µl)                    31.250 
*Solution E (µl)                      2.063 
Distilled water (ml)                      1.988 
Total volume (ml)                      20.00 
 *added prior to use 
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2.2.4.4.2 Equilibration of IPG strips 
           A hundred mg of DTT was dissolved in 10 ml of SDS equilibration buffer.  Five 
ml of the solution was pipetted into a tube containing an IPG strip.  Tubes were shaken 
for 15 minutes.  The DTT-SDS equilibration solution was then discarded.  Two hundred 
fifty mg of iodoacetamide was dissolved in 10 ml of the same buffer and the solution 
was added and shaking was further carried out for another 15 minutes.  The IPG strip 
was quickly rinsed with electrophoresis buffer after the equilibration solution was 
discarded.  The strip was then placed on top of the gel and sealed with agarose solution. 
 
2.2.4.4.3  Second dimension separation 
          Second dimension electrophoresis was performed in two steps as shown below: 
             Step          Voltage (V)        Current(mA)            Walt (W) 
               1               50               17*              2* 
               2              600               25*             15* 
*per gel 
 
The whole experiment was conducted at a constant temperature of 16
o
C.  After 
electrophoresis, the gel was removed carefully from the cassette and was ready for 
staining or Western blotting.  
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2.2.4.4.4  Silver staining of 2-DE gels 
Stock solutions 
Fixing solution 
(40% (v/v) ethanol, 10% acetic acid) 
          Ethanol                                                              400 ml 
          Acetic acid                                                         100 ml 
The solution was made up to 1 L with distilled water. 
 
Sensitizing solution  
(30% (v/v) ethanol, 0.5 M sodium acetate, 8 mM sodium thiosulphate, 0.5% (v/v) 
glutaraldehyde) 
          Ethanol                                                                  300 ml 
          Sodium acetate trihydrate                                       68 g 
          Sodium thiosulphate                                               20 g 
Solution was made up to 1 L of distilled water and 5 ml of glutaraldehyde was added 
prior to use. 
 
Silver solution 
(14.25 mM silver nitrate, 0.04% (v/v) formaldehyde) 
          Silver nitrate                                                            2.5 g 
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Solution was made up to 1 L with distilled water. Four hundred µl of formaldehyde was 
added prior to use. 
 
Developing solution  
(0.4 M sodium carbonate, 5% sodium thiosulphate, 0.2% (v/v) formaldehyde) 
          Sodium carbonate                                                      25 g 
          Sodium thiosulphate                                                  28 µl 
Solution was made up to 1 L with distilled water. Four hundred µl of formaldehyde was 
added prior to use. 
 
Stopping solution 
(40 mM EDTA-Na2.2H2O) 
         EDTA-Na2.2H2O                                                          14.6 g 
Solution was made up to 1 L with distilled water. 
 
Preserving solution: 10% (v/v) glycerol 
Staining protocol           
After completion of the 2-DE, gels were immersed in fixing solution for 30 
minutes.  The gels were then placed in sensitizing solutions overnight.  After the 
incubation, the gels were washed three times for 5 minutes with distilled water.  The 
silver reaction was carried out by immersing the gel in the silver solution for 40 
minutes. 
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The gels were rinsed with distilled water to remove excess silver solution.  The 
developing solution was then poured into the container which contained the gels.  Once 
protein spots appeared, the gels were soaked in stopping solution for 30 minutes.  The 
developed gels were washed with distilled water and stored in preserving solution at 
room temperature.  For mass spectrometric analysis, the gels were stained in absence of 
glutaraldehyde.   
 
2.2.5  Western blotting 
           Semi-dry transfer system (Novablot Kit for the Multiphor II Electrophoresis 
System, GE Healthcare Biosciences, Uppsala, Sweden) was used for the protein transfer 
process. 
 
2.2.5.1 Conjugation of CGB and CMB lectins to enzymes 
To develop human urinary glycoprotein map, the urinary proteins which were 
resolved using 2-DE were electrophoretically transferred to the nitrocellulose 
membranes.  The membranes were probed with enzyme conjugated lectins to form 
lectin-glycoprotein complexes.  The complexes were then detected with colorimetric 
reagent specific for the enzymes. 
 
2.2.5.1.1 Conjugation of CGB lectin to Horseradish Peroxidase  
Stock solutions 
0.1 M Sodium periodate 
          Sodium periodate                                           21.39 mg 
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The chemical was dissolved in 1 ml of deionised distilled water. The solution was 
prepared fresh prior to use. 
 
1 M Sodium acetate buffer, pH 4.4 
          Sodium acetate                                                8.20 g/L 
          Acetic acid                                                        6.0 g/L 
Sodium acetate solution was mixed with acetic acid solution at a ratio of 1:2.  
 
0.1 M Sodium carbonate buffer, pH 9.5 
          Sodium carbonate                                               10.6 g/L 
          Sodium hydrogen carbonate                               8.4 g/L 
Sodium carbonate solution was added to the sodium hydrogen carbonate solution until 
pH 9.5 was obtained. 
 
0.4% (w/v) Sodium borohydride 
          Sodium borohydride                                              4.0 mg 
Sodium borohydride crystal was dissolved in 1 ml of distilled water. 
 
0.1 M borate buffer, pH 7.4. 
          Disodium tetraborate                                            9.54 g/ 250 ml 
          Boric acid                                                             24.73 g/ 4L 
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One hundred and fifteen ml of borate solution was added to 4 L of boric acid to pH 7.4. 
 
Conjugation protocol 
Four mg of horseradish peroxidase (HRP) was dissolved in 1 ml of distilled 
water. Two hundred μl of 0.1 M sodium periodate solution was added to the HRP 
solution and a green coloured solution was obtained.  The solution was then dialysed 
overnight against 0.1 mM sodium acetate buffer, pH 4.4 at 4
o
C.  The dialysate was 
stirred for 20 minutes at room temperature and its pH was raised to 9.5 by the addition 
of 25 μl of 0.1 M sodium carbonate buffer, pH 9.5.  This was immediately followed by 
the addition of 1 ml of CGB lectin (2 mg/ml) and the mixture was left to stir for 2 hours 
at 4
oC.  The product was then reduced by addition of 100 μl of fresh sodium 
borohydride solution (4 mg/ml) and left to stand for another 2 hours at 4
o
C.  The HRP-
conjugated CGB lectin was dialysed overnight against 0.1 M sodium borate buffer pH 
7.4 at 4
o
C.  Finally, the conjugated lectin was diluted in equal volume of 60% glycerol 
in borate buffer and stored in eppendorf tube at 4
o
C. 
 
2.2.5.1.2 Conjugation of CMB lectin to Alkaline Phosphatase 
Stock solution  
1 M sodium carbonate/hydrogen carbonate buffer, pH 9.4 
          Sodium carbonate                                       10.6 g/100 ml 
          Sodium bicarbonate                                       8.4 g/100 ml 
The pH of sodium bicarbonate was adjusted to 9.4 by the addition of sodium carbonate. 
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100 mM sodium carbonate/hydrogen carbonate buffer, pH 9.8 
Ten ml of 1 M sodium carbonate/hydrogen carbonate buffer was diluted to 100 ml with 
deionised distilled water. 
 
 200 mM sodium borohydride 
Eight mg of sodium borohydride was dissolved in 1 ml of cold deionised distilled water. 
 
 2 M triethanolamine solution, pH 8.0 
 Three ml of dionised distilled water was added to 2.66 ml of triethanolamine solution. 
The pH of the solution was adjusted to 8.0 with HCl and made up to 10 ml with 
deionised distilled water. 
 
 1 M glycine, pH 7.0 
          Glycine                                                               0.75 g 
Glycine was dissolved in 6 ml deionised distilled water and the pH was adjusted to 7.0 
with 0.1 M NaOH. The solution was then made up to 10 ml with deionised distilled 
water. 
 
 Triethanolamine buffer, pH 7.6 
(50 mM Triethanolamine, 150 mM NaCl, 1mM MgCl2, 0.1 mM ZnCl2, 10mM 
glycine and 0.1 % (w/v) sodium azide) 
          Triethanolamine                                       16.65 ml 
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          NaCl                                                        21.92 g 
          MgCl2                                                       0.51 g 
          ZnCl2                                                                                  34.0 mg 
         Glycine                                                         1.88 g 
         Sodium azide                                                                                     2.5 g 
The buffer was prepared by dissolving the above salts with 2.5 L of distilled water. 
 
Conjugation Protocol 
      CMB lectin was concentrated to the final concentration of 7 mg/ml prior to the 
conjugation.  Fifty µl of the concentrated CMB lectin was mixed with 100 μl of alkaline 
phosphatase (AP) solution and incubated overnight at 4
o
C.  Conjugation was terminated 
by adding 20 μl of 2 M triethanolamine solution, pH 8.0 followed by 40 µl sodium 
borohydride solution.  The solution was stirred and incubated for 30 minutes at 4
o
C.  
Five µl of triethanolamine was then added to the mixture and followed by 2 hours 
incubation at 4
oC.  Ten μl of 1 M glycine solution pH 7.0 was added to the mixture. 
Then, the mixture was dialysed extensively against four changes of triethanolamine 
buffer. Sodium azide was added to the solution to the final concentration of 1 mg/ml. 
The alkaline phosphatase conjugated CMB lectin was aliquoted and stored at -80
o
C. 
 
2.2.5.2 Protein transfer Western blotting  
Stock Solution 
Transfer buffer  
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(40 mM glycine, 0.1 M Tris, 0.038% (w/v) SDS, 20% (v/v) methanol) 
          Glycine                                                                 2.93 g 
          Tris                                                                        5.81 g 
          SDS                                                                      0.375 g 
          Methanol                                                               200 ml 
The chemicals were dissolved and made up to 1 liter with distilled water. 
 
Tris buffered saline-Tween (TBS-T)  
(TBS with 0.1% (v/v) Tween-20) 
          TBS                                                                         1 liter 
          Tween-20                                                                 1 ml 
 
Protein transfer protocol 
Twelve pieces of filter paper and a piece of nitrocellulose membrane, 0.45 μm 
was cut according to the size of the gel.  The gel, the filter papers and the nitrocellulose 
membrane were immersed in the transfer buffer for 15 minutes.  Six electrode papers 
were placed on the anode plate followed by the membrane, the gel and lastly with 
another six filter papers.  A tube was used to roll out any trapped air bubbles. Then, the 
cathode tray was placed on the top of the sandwiched gel.  The transfer was performed 
for one hour at a constant current of 0.8 mA/cm
2
. 
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2.2.5.3 Protein detection using HRP conjugated CGB lectin 
           The nitrocellulose membrane was blocked using TBS-T containing 3% gelatin 
for one hour on a shaker at room temperature.  It was then washed trice with TBS-T for 
5 minutes each.  The blot was incubated with HRP conjugated CGB lectin in TBS-T at 
an optimal concentration of 1 µg/ml at 4
o
C overnight.  The wash step was repeated 
twice. The membrane was developed using metal enhance DAB solution kit (Pierce, 
Illinois), prepared based on the manufacturer’s protocol.  The development reaction was 
stopped by washing the membrane with distilled water.  The membrane was air dried 
prior to scanning. 
 
2.2.5.4 Protein detection using AP conjugated CMB lectin 
           The procedure for the detection of CMB lectin linked glycoprotein was similar 
as described in Section 2.2.5.3.  However, the incubation procedure was replaced with 
AP conjugated CMB lectin at 1:10000 dilution.  To develop the membrane, the 
membrane was incubated in NBT/BCIP solution, which was prepared by dissolving one 
NBT/BCIP tablet in 10 ml of distilled water.  The development reaction was stopped by 
washing the membrane with distilled water.  The membrane was air dried prior to 
scanning. 
 
2.2.6  Image analysis 
           Silver stained 2-DE gels and lectin resolved blots were scanned using an Image 
Scanner III (GE Healthcare Biosciences, Uppsala, Sweden).  Analysis of each 
glycoprotein spot and protein spot was performed using Image Master Platinum 7.0 
software (GE Healthcare Biosciences, Uppsala, Sweden).  Percentage of volume 
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contribution refers to the spot volume of a protein which was expressed as a percentage 
of the total spot volume of all detected proteins.  All values are presented as 
mean±S.E.M. The Student’s t-test was used to analyze the significance of differences 
between normal subjects and patients.  The false discovery rate control was carried out 
using the method of Benjamini and Hochberg (Benjamini and Hochberg, 1995).  
 
2.2.7  Sample preparation for MS analysis 
2.2.7.1   In-gel digestion 
             For the protein identification by mass spectrometry, proteins resolved by 2-DE 
has to be digested first.  Before the in-gel digestion was performed, the desired protein 
spot was excised manually from the modified silver-stained gels and put in a 
microcentrifuge tube containing deionized distilled water.  The gel plugs were destained 
using 15 mM potassium ferricyanide in 50 mM sodium thiosulphate pentahydrate until 
they were transparent.  They were further reduced and alkylated using 10 mM DTT in 
100 mM ammonium bicarbonate and 55 mM iodoacetamide in 100 mM ammonium 
bicarbonate, respectively. Then, the gel plugs were washed with 50% acetonitrile in 100 
mM ammonium bicarbonate and 100% acetonitrile and followed with dehydration using 
vacuum centrifugation.  The dried plugs were incubated overnight in 25 µl of 6 ng/µl 
trypsin in 50 mM ammonium bicarbonate at 37
o
C.  Finally, the peptides were dried 
using a vacuum centrifugation and prepared for MS analysis. 
 
2.2.7.2 On-membrane digestion 
           The on-membrane digestion was done for MS analysis of peptide extracted from 
a nitrocellulose membrane.  After electoblotting, the proteins onto a nitrocellulose 
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membrane, the membrane was blocked with 0.5 ml 1% PVP-40 (w/v) in TBS, washed 
three times with the same buffer and detected using lectins as described in Section 2.2.5.  
The protein spots of interest was excised carefully and destained with 0.5 ml 0.1% 
EDTA dihydrate for 30 minutes.  Then, the nitrocellulose spots were washed three times 
with 0.5 ml of 0.5 and 1.0 M melibiose in 50 mM Tris-HCl pH 7.5 for 30 minutes each 
at room temperature to strip the horseradish peroxidase-conjugated CGB lectin. 
Similarly,  the nitrocellulose spots were also washed three times with 0.5 ml of 0.5 and 
1.0 M methyl-α-D-mannopyranoside in 50 mM Tris-HCl pH 7.5 for 30 minutes each at 
room temperature to strip the alkaline phosphatase-conjugated CMB lectin.  Then, the 
stripped spot was blocked with 0.5 ml 0.5% (w/v) PVP-40 in 100 mM acetic acid at 
37
o
C for 30 minutes.  After that, the spots were washed at least six times with deionized 
distilled water to remove PVP-40.  The protein spots were digested with trypsin in 50 
mM sodium bicarbonate at a final concentration 12.5 ng/µl and incubated overnight at 
37
o
C.  After digestion, the samples were dried with a vacuumed centrifugation and then 
dissolved in acetone (22.5 μl per mm2 of spot area). Then, it was vortexed and incubated 
for 30 minutes at room temperature.  After incubation, the acetone was carefully 
removed and the precipitated peptides were air-dried and prepared for mass 
spectrometry analysis. 
 
2.2.7.3 Mass spectrometry analysis 
           Peptides obtained from both gels and membranes were reconstituted with 0.1% 
formic acid and desalted using ZipTip C18 reversed phase media (Millipore, MA, USA). 
The peptides were mixed with 10 mg/ml of CHCA in 1% TFA in 50:50 
acetonitrile/water.  Seven μl of the peptides were then spotted on the Opti-TOF 384 well 
insert (Applied Biosystem/MDS Sciex, Toronto, Canada).  The samples were analyzed 
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on the 4800 Plus MALDI TOF/TOF analyzer (Applied Biosystem/MDS Scienx) with 
the mass standard kit (Applied Biosystem/MDS Scienx) served as the calibrator for the 
resulting MS and MS/MS mass spectra scales. 
 
2.2.7.4 Protein identification 
           Protein spots were analyzed using MASCOT search engine (Matrix Science, 
London, UK) against Homo sapiens entries in the Swiss-Prot database.  The following 
parameters were used in the MASCOT Ion Search: 1) enzyme trypsin was used. 2) one 
missed cleavage was allowed. 3) fixed modification was carbamidomethyl (cystein) 4) 
variable modification was oxidation (methionine) 5) mass tolerance for precursor 
ion/peptide tolerance was 50 ppm. 6) mass tolerance for fragment ion/ms/ms tolerance 
was 0.1 Da. 7) Only monoisotopic mass were included in the search. 
 
2.2.8 Enrichment of urinary glycoprotein using CGB and CMB lectins affinity 
column 
Stock solutions 
0.1 M sodium bicarbonate pH 8.5 
            Sodium bicarbonate                                               8.4 g 
Sodium bicarbonate was dissolved in 800 ml of distilled water and then the pH was 
adjusted to 8.5 and the buffer was topped up to 1 L. 
 
0.1 M sodium chloride 
          Sodium chloride                                                 58.44 g 
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Sodium chloride was dissolved in 1 L of distilled water. 
 
1.0 M ethanolamine, pH 9.0 
             Ethanolamine                                                        11.8 ml 
One hundred and eighty ml of distilled water was added to 11.8 ml of ethanolamine and 
the pH was adjusted to pH 9.0 with HCl. 
 
2.2.8.1 Preparation of lectin affinity column 
           Four gram of CNBr pre-activated Sepharose 4B gel was stirred overnight with 
100 ml of cold distilled water at 4
o
C.  Twelve ml of rehydrated gel was washed with 2 
liter of cold distilled water followed with 1 L 0.1 M sodium bicarbonate, pH 8.5.  Then, 
the rehydrated gel was incubated with 12 ml of lectin solution with the concentration of 
4 mg/ml under a gentle stirring for 20 hours at 4
o
C.  The conjugated Sepharose was then 
transferred into a sintered funnel and washed with 200 ml of 1.0 M sodium chloride and 
200 ml distilled water.  The Sepharose was suction-dried to a wet cake and then stirred 
in 100 ml 1.0 M ethanolamine, pH 9.0 for 1 hour at 4
o
C.  After the blocking step, the 
Sepharose was washed with 1 L of 1.0 M sodium chloride and 1 L of distilled water.  
Lastly, the Sepharose was poured into a column and washed with PBS buffer, pH 7.2. 
 
2.2.8.2 Affinity separation of glycoprotein using CGB and CMB lectin affinity 
column 
           To prepare the sample for the affinity chromatography, 400 μg of pooled 
urinary protein samples from eleven control subjects, seven ECa patients, nine OCa 
patients and eight CCa patients were respectively dissolved with 1 ml 0.1 M PBS, pH 
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7.2 and loaded into four separate columns.  They were left to stand overnight to allow 
glycoprotein binding.  The first fraction prior to the washing process was collected as an 
unbound protein fraction.  The column was washed with 0.1 M PBS, pH 7.2 and 1 ml of 
wash fractions were collected in a microcentrifuge tube.  The entire washing process 
was monitored at 280 nm.  The washing process was performed until the absorbance fell 
to the baseline.  To elute the bound glycoprotein, the column was washed with the 
elution buffer (0.1 M melibiose for CGB lectin or 0.1 M methyl-α-D-mannopyranoside 
for CMB lectin in 0.1 M PBS buffer, pH 7.2).  The column was left to stand overnight 
to ensure complete detachment of glycoproteins from the respective lectins.  Fractions 
of eluted glycoproteins were collected in microcentrifuge tubes which were labeled as 
bound fractions. Regeneration of column was performed by washing the column again 
with 10 column bead volumes of PBS buffer followed with 5 column bead volumes of 
0.1% Triton X-100 at 37
o
C and lastly equilibrated with 2 ml of PBS buffer. 
 
2.2.8.3 Analysis of bound fraction with LC-MS/MS 
           The bound fractions were pooled, dialyzed and concentrated with Vivaspin 
column concentrator (Sartorius Stedim Biotech, Goettingen, Germany).  The 
concentrated bound fractions were lyophilized and sent to The Vincent Coates 
Foundation Mass Spectrometry Laboratory, Stanford University, USA, for LC-MS/MS 
analysis.  
 
2.2.8.4 Protein identification and spectral counting   
           The LC-MS/MS data were viewed and analyzed using Scaffold version 3.4.5 
software.  The protein identification was done by submitting the raw MS/MS data to the 
MASCOT search engine (Matrix Science, London, UK) against Homo sapiens entries in 
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the Swiss-Prot database.  The following parameters were used to match the peptide: 1) 
enzyme trypsin was used. 2) one missed cleavage was allowed. 3) fixed modification 
was propionamide 4) variable modification was oxidation (methionine) and acetylation 
5) mass tolerance for precursor ion/peptide tolerance was 20 ppm. 6) mass tolerance for 
fragment was 1.0 Da.  The identity of a peptide was considered valid when XCorr value 
was greater than 0.8 for singly charged ions, 1.9 for doubly charge ions and 2.6 for 
triply charged ions and have a minimum peptide length of seven amino acids.  The 
subcellular location and the glycosylation type of the identified proteins were searched 
from the Swiss-Prot database.  Additionally, the potential O-or N-glycosylation of the 
identified protein were determined with NetOGlycan 3.1 
(http://www.cbs.dtu.dk/services/NetOGlycan) and NetNGlyc 1.0 
(http://www.cbs.dtu.dk/services/NetNGlyc/).  The spectral of the proteins were 
normalized with Normalized Spectral Abundance Factors (NSAF)  and subjected to the 
comparison between control and cancer groups (Florens et al., 2006; Zybailov et al., 
2006).  NSAFs were used to estimate the protein level, in which the values closer to 1 
indicating higher protein level.     
 
The NSAF for a protein k is the number of spectral counts of a protein (k) divided by 
the protein’s length, divided by the total number spectral counts for all N proteins.   The 
ratio of change was calculated by dividing the NSAF value of cancer cohort over the 
NSAF value of control.  The ratio value greater or equal to 1.6 was considered increase 
in expression of a protein, while the ratio value lesser or equal to 0.67 was considered 
decrease in expression of a protein.          
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2.2.9 Competitive ELISA 
Standard solutions 
Binding buffer 
(0.05 M sodium bicarbonate buffer, pH 9.6) 
          Sodium carbonate                                               1.59 g 
          Sodium hydrogen carbonate                    2.93 g 
Both salts were dissolved in 1 L of distilled water 
 
Blocking buffer: 0.5% gelatin in PBS-T 
 
Washing buffer: PBS with 0.05% (v/v) Tween-20 
 
Stopping solution: 2M sulphuric acid (H2SO4) 
 
ELISA protocols 
           Ten μg of freeze-dried urine samples were dissolved with 50 μl of binding buffer 
and loaded to microtitre plates (Nunc, Denmark) for coating overnight at 4 
o
C.  The 
wells were rinsed extensively with 100 μl of washing buffer for three times.  Non-
coated sites were blocked with 100 μl of blocking buffer for 30 minutes in room 
temperature.  After blocking, the plates were washed and incubated with mouse anti-
human CLU (BioRad Laboratories Inc., U.S.A.) (MCA2612, 1.0 mg/ml) in the presence 
of controls’ and patients’ urines at dilution 1:1000 in PBS-T for 1 hour at room 
temperature.   Positive controls were prepared in the absence of urine samples.  Blanks 
were prepared by addition of washing buffer. 
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After incubation, each wells were washed extensively with washing buffer and 
followed by additional of 200 μl of HRP labelled secondary anti-mouse IgG at dilution 
1:5000.  Plates were incubated for another 1 hour at room temperature and then washed 
with washing buffer.  One hundred μl of 3,3’,5,5’-tetramethylbenzidine substrate 
(Sigma Aldrich Company, St. Louis, U.S.A) were added to each wells and incubated for 
15 minutes at room temperature in the dark. The reaction was terminated by the addition 
of 100 μl stopping buffer after the incubation period. Absorbance values were read at 
450 nm using an ELISA plate reader. The amount of CLU in urine samples was 
determined with the percentage of inhibition of substrate hydrolysis.  The formula is 
percentage of inhibition = [1-(sample absorbance/positive control absorbance)] X 100 
(Reddington et al., 1991). 
 
2.2.10  Lectin-ProteinChip array for SELDI-TOF analysis 
Standard solutions 
Trypsin denaturation solution  
(8 M urea, 50 mM Tris-HCl, 2 mM DTT, pH 8) 
          Urea                                                                    4.8 g 
            Tris base                                                               61 mg 
           DTT                                                                      3.09 mg 
The chemicals were dissolved in 5.0 ml and the pH of the solution was adjusted using 
1.0 M HCl.  The solution was topped up to 10 ml with distilled water.   
 
Coupling buffer: PBS, pH 7.5 
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Blocking buffer: 1 M Ethanolamine in PBS, pH 7.5 
          10 X PBS                                                                 10 ml 
          Deionised distilled water                                         70 ml 
          Ethanolamine                                                           11.8 ml 
The solution was mixed and the pH of the solution was adjusted to pH 7.5 with 1.0 M 
NaOH.  The solution was topped up to 100 ml with distilled water. 
 
Wash buffer: 0.5% Triton-X in PBS 
 
Matrix: α-cyano-4-hydroxycinamic acid (CHCA) 
 
2.2.10.1 Sample preparation 
           Freeze-dried urine sample, which was stored in -80
o
C freezer prior to SELDI-
TOF analysis, was reconstituted with 100 μl of 50 mM ammonium bicarbonate.  Then, 
5 μl of 200 mM DTT stock solution was added to the solution. The solution was boiled 
for 10 minutes at 95
o
C before 4 µl of 1 M iodoacetamide was added to the solution.  
After the mixture was vortexed and followed by a quick spin, it was incubated for 1 
hour at room temperature.  Then, the solution was added with 20 µl of DTT, vortexed, 
spun and incubated for another 1 hour at room temperature.  The sample was incubated 
with 10 μl of 100 ng/µl trypsin in 50 mM ammonium bicarbonate overnight at 37oC.  
After digestion, 25 μl of trypsin denaturation solution was added to the solution and the 
mixture was boiled at 95
o
C for 15 minutes.  Finally, the solution was dried with vacuum 
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centrifugation.  The peptides were reconstituted with 0.1% formic acid and carefully 
desalted using ZipTip C18 reversed phase media (Millipore, MA, USA).  Lastly, it was 
let to dry at room temperature.  
 
2.2.10.2 Immobilization of CGB  and CMB lectin to pre-activated array 
          The immobilizations of CGB and CMB lectins were performed as described by 
the manufacturer with some modifications.  Firstly, each spot was wetted with 2 µl of 
50% acetonitrile/deionized distilled water briefly and then the solution was removed 
with the edge of a kimwipe.  The spot was then activated by adding 2 μl of PBS and the 
chip was incubated in a humidity box for 15 minutes at room temperature.  The PBS 
was then removed with the edge of a kimwipe.  Next, lectin immobilization was 
performed by adding 5 µl of 1.0 mg/ml of lectin in 0.1 M sodium bicarbonate buffer 
(pH 8.0) on the spot and the chip was incubated for 1 hour at room temperature. After 
the incubation period, the lectin solutions were removed from the spots.  The residual 
active sites on the spots were blocked with 5 μl of blocking buffer and it was incubated 
for 30 minutes.  The spots were then washed twice with washing buffer and three times 
with PBS by pipetting the buffer up and down for 15 times.  The samples were prepared 
as described as Section 2.2.10.1.  It was mixed with 5 μl of washing buffer and added 
onto spots and incubated overnight at 4
o
C.  After incubation, the spots were washed 
twice with 5 μl of wash buffer, twice with PBS and finally rinsed with MiliQ water.  
One µl of matrix was added to each spot and mass analysis was performed in a 
PCS4000 ProteinChip reader, Enterprise edition (BioRad Laboratories Inc., U.S.A.) 
with a combination of 130 laser shots at optimum laser energy at 1500 nJ for each spot. 
Each sample was analyzed in duplicate.  
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2.2.10.3 Data analysis of lectin captured glycopeptides 
           The raw data were analyzed with ProteinChip Data Manager Software 4, 
Enterprise edition (BioRad Laboratories Inc., U.S.A.).  Peak detection was performed 
by Expression Difference Mapping which involved the baseline subtraction and 
automatic peak detection.  The peaks were detected between 1 kDa to 10 kDa and 
generated a list of peak clusters using the setting of five times to the signal-to-noise 
(S/N) ratio for the first pass and and two times to the S/N ratio for second pass.  The 
statistical analysis using Wilcoxson signed-rank test was subsequently performed for all 
peak intensity values of control and three cohorts of cancer.  A p-value of less than 0.05 
was considered to be statistically significant.  To enable the peak clusters to be analyzed 
by Biomarker Pattern Software 5.0, the expression difference mapping (EDM) file was 
initially converted to csv. file.  The biomarker pattern of control and three cohorts of 
cancers was identified which subsequently was used to construct the diagnostic model 
of CGB or CMB lectin captured urinary glycopeptides profile.   
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Chapter 3 
Results 
 
 
 
 
 
 
Results 
78 
 
CHAPTER 3:  RESULTS 
 
3.1  Isolation and purification of Champedak Galactose-Binding (CGB) and 
Champedak Mannose-Binding (CMB) lectins 
The crude extract of champedak seeds was prepared as described in Section 
2.1.1.  The CGB and CMB lectins were then isolated from the crude seed extract by 
affinity column chromatography using immobilized galactose and mannose to capture 
the CGB and CMB lectins, respectively (Section 2.2.1).  Figures 3.1a and 3.1b 
demonstrate the typical profiles generated from elution of the CGB and CMB lectins by 
the respective sugar affinity columns.  Both lectins appear to have been eluted as single 
sharp peaks, which is a reflection of the purity of the eluted proteins. 
 
3.2  Determination of the concentrations of CGB and CMB lectins  
  Estimation of protein concentrations of 5 ml CGB and CMB lectin extracts was 
performed using the BCA protein assay kit (Pierce, Rockford, Illinois).  A standard 
calibration curve of absorbance values over several concentrations of BSA was 
constructed.  Figure 3.2 shows a typical calibration curve obtained from the protein 
assay.  Based on the extrapolated standard curve, the concentrations of the CGB and 
CMB lectins were approximately 720 µg/ml and 260 µg/ml, respectively.  In addition, 
the yield per gram of CGB and CMB lectins’ wet weight were 3.5 mg and 1.2 mg, 
respectively. 
 
3.3  Determination of purity of CGB and CMB lectins 
           The affinity isolated lectins were subjected to SDS-PAGE electrophoresis using 
18% separating gel to confirm for their purity.  Figure 3.3 shows the SDS-PAGE 
Results 
 
 
 
 
 
 
Figure 3.1: Typical elution profiles of CGB and CMB lectin 
Panel A demonstrates the elution profile of CGB lectin when crude lectin was subjected 
to the immobilized galactose-Sepharose affinity column chromatography. Fractions 
collected from the galactose column were monitored at absorbance of 280 nm. The 
unbound fractions with high absorbance were kept for CMB lectin isolation. Washing 
was performed using PBS, pH 7.2 to eliminate unbound substances until a baseline 
reading was achieved. CGB lectin was eluted with 0.8 M D-galactose in PBS buffer and  
arrow indicates the start of elution. Panel B demonstrates the isolation of CMB lectin 
from the unbound fractions of galactose-Sepharose column using mannose-Sepharose 
column. Arrow indicates the start of elution for CMB-lectin using 0.8 M D-mannose in 
PBS buffer. 
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Figure 3.2: Standard curve for protein concentration estimation 
A typical standard curve was constructed based on serial dilutions of BSA. BSA was 
diluted to obtain protein concentrations ranging from 0 to 2 mg/ml. Estimation of CGB 
and CMB lectin concentrations was made by referring to a standard curve. Absorbance 
of the complex formed was measured at 562 nm.   
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Figure 3.3: SDS-PAGE analysis of purified CGB and CMB lectin 
The purified CGB and CMB lectins were subjected to 18% SDS-PAGE, followed by 
Coomassie Brilliant blue staining to check its purity. Under reducing condition, CGB 
lectin was resolved into two bands with Mr of approximately 14,500 Da and 16,000 Da 
while CMB was resolved into only one band with Mr of approximately 15,000 Da. 
Lane 1: Pre-stained SDS-PAGE marker consisting of ovalbumin (53,541 Da), carbonic 
anhydrase (37,134 Da), soybean trypsin inhibitor (29,134 Da). lysozyme (19,540 Da) 
and aprotinin (6,905 Da)  
Lane 2: CMB lectin 
Lane 3: CGB lectin 
6.905 Da 
19,540 Da 
29,134 Da 
37,134 Da 
53,541 Da 
 + 
- 
Results 
82 
 
analysis of the affinity purified CGB- and CMB-lectins.  Electrophoresis was performed 
under reducing conditions as described  in  Section 2.2.3.4.    Under this condition, the 
CGB lectin was resolved into two bands with relative molecular weights of 
approximately 14,500 and 16,000 Da.  The CMB lectin, on the other hand, was resolved 
into a single band with relative molecular weight of approximately 15,000 Da.  These 
bands were the characteristic bands of the CGB and CMB lectins that were earlier 
established (Lim et al., 1997; Abdul Rahman et al., 2002).  There were no other bands 
observed in this SDS-PAGE gel, indicating that the lectins were pure. 
 
3.4  Determination of urinary protein concentration 
            The concentrations of urinary protein samples were determined using a similar 
method as that used for the determination of the concentrations of the lectins.  The 
control urine samples apparently contain lower amounts of proteins compared to the 
urine samples of the groups of patients with three different types of cancers (Table 3.1).   
 
Table 3.1: Concentration of protein in urine samples  
Urine samples Concentration of urinary protein 
(μg/ml) 
Control (n=11) 101.302 ± 10.670 
ECa       (n=7) 355.292 ± 106.420* 
OCa       (n=9) 648.215 ± 126.840* 
      CCa       (n=8) 372.837 ± 90.230* 
            All values were expressed as mean±S.E.M.  
*statistically significant compared to control when p<0.05. 
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3.5  Two-dimensional electrophoretic analysis 
3.5.1  2-DE urinary protein profiles of controls and patients with ECa 
           The urinary proteins of the control female subjects were subjected to 2-DE 
followed by silver staining.  Comparable 2-DE urinary protein profiles were generally 
obtained for all samples analysed.  Figure 3.4a shows a representative 2-DE urine 
profiles of controls and patients with ECa.  There were seven protein clusters which 
were highly resolved and consistently appeared in all the proteome maps of the controls.  
Furthermore, the intensities of these protein clusters were not significantly different 
between the 11 control samples analysed.  At this stage, preliminary identification of 
protein spots was performed by visually comparing the 2-DE profiles of the urinary 
proteins that were generated in this study with the earlier established 2-DE urine 
proteome map of Candiano et al. (2010).   
 
Since the 2-DE urinary protein profiles of patients with OCa and CCa have been 
earlier established by Abdullah-Soheimi et al. (2010), this part of the study focused 
solely on patients with ECa.  When the urinary proteins from seven patients with ECa 
who were newly diagnosed and untreated were resolved with 2-DE, a similar pattern of 
protein distribution was obtained for all the seven proteins that consistently appeared in 
the 2-DE gels.  Proteins that were resolved in both control and ECa groups samples 
were kininogen-1 (KNG), alpha-1 acid glycoprotein (AAG), zinc alpha-2 glycoprotein 
(ZAG), CD59, protein AMBP (AMBP), Ig gamma 3 chain C region (IGHG3) and Ig 
kappa chain C region (KAC).  
 
 
Results 
 
 
 
 
 
Figure 3.4: Typical 2-DE urine profiles of controls and patients with ECa  
Urinary proteins from controls and patients with ECa were separated according to their 
isoelectric points and molecular mass. Panel A and panel B demonstrate representative 
2-DE urinary protein profiles of controls and patients with ECa, respectively. The 
labeled protein clusters are proteins which were consistently observed in both groups. 
The acidic side of the gel is to the left and relative molecular mass declines from the 
top.    
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3.5.2  Image analysis of 2-DE urinary protein profile of controls and ECa patients  
           The silver-stained 2-DE urinary protein profiles of controls and patients with 
ECa were scanned and analyzed using the Image Master Platinum Software version 7.0. 
All well-resolved protein spots were estimated for their percentage of volume 
contribution.  Volume analysis of urinary proteins in the 2-DE profiles of controls and 
patients demonstrated the similar results for some of the proteins, except for AAG, ZAG 
and CD59.  The intensities of AAG and ZAG were more than 10-fold higher while the 
intensity of CD59 protein clusters was much lower in the 2-DE urinary profiles of 
patients with ECa.  These values were found to be significantly different between both 
groups when analyzed with the Student t-test followed by the false discovery rate 
control, based on the method of Benjamini and Hochberg.  Table 3.2 shows the mean 
percentage of volume contribution of the seven urinary proteins that consistently 
appeared in controls and patients with ECa. 
 
Table 3.2 Mean percentage of volume contribution of urinary proteins  
Urinary 
proteins 
Mean % Vol ± SEM 
P 
Fold 
changes* Control ECa 
AAG    0.161 ± 0.072 2.746 ± 0.717 0.001 +13.03 
ZAG 0.175 ± 0.045 2.184 ± 0.592 0.001 +10.59 
CD59 2.575 ± 0.497 0.177 ± 0.070 0.002 –14.55 
KNG 5.137 ± 1.826 0.945 ± 0.491 0.108 ns 
IGKC 14.785 ± 2.197 18.840 ± 2.651 0.286 ns 
AMBP 8.941 ± 1.706 12.837 ± 3.430 0.306 ns 
IGHG3 4.014 ± 1.221 4.554 ± 1.706 0.807 ns 
*Fold expression changes are relative to the control values; (+) increase in expression; 
(–) decrease in expression; ns – not statistically significant; A p-value of less than 
0.0214 was considered significant. 
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3.6  Profiling of urinary glycoproteins of controls and patients with ECa, OCa 
and CCa using 2-DE and lectins  
3.6.1  CGB lectin detected 2-DE urinary glycoprotein profile 
           To obtain profiles comprising only O-glycosylated urinary glycoproteins, the 2-
DE separated urinary proteins of patients and controls were transferred onto the 
nitrocellulose membrane and probed with enzyme-conjugated CGB lectin.  The 
glycoprotein profile obtained was then compared to the earlier established 2-DE urine 
proteome map of Candiano et al. (2010) as well as the silver-stained 2-DE urinary 
protein profile that was earlier described in this study (Section 3.5.1).  The O-
glycosylated urinary protein profiles developed with enzyme-conjugated CGB lectin 
were entirely different from the 2-DE urinary protein profiles generated by silver 
staining.  Six clusters of O-glycoproteins were consistently detected in the urinary 
membrane profiles of controls and patients’ samples. In addition, one O-glycoprotein 
spot, with a molecular mass of approximately 51 kDa, seemed to appear in the profiles 
of all the control samples that were analyzed but faintly appeared in only one of the 
urine samples from patients with ECa.  Six clusters of O-glycosylated urinary 
glycoproteins were consistently detected in all O-glycosylated urinary glycoproteome 
profiles which were Ig alpha-1 chain C region (IGHA1), KNG, inter alpha trypsin 
inhibitor heavy chain H4 (ITIH4), AMBP, heparan sulfate proteoglycan 2 (HSPG2) and 
transgelin (TAGLN).  In addition, two O-linked urinary glycoprotein spots or clusters of 
hemopexin (HPX) and leucine rich alpha-2 glycoprotein (LRG) appeared with low 
intensity in the O-glycosylated urinary glycoproteome profiles of some controls or 
patients samples.  There were two additional  protein spots or clusters that were not 
detected in the 2-DE silver stained profiles but were clearly resolved in the O-
glycosylated urinary glycoproteome profiles.  They were identified as nebulin (NEB) 
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and CLU with mass spectrometry analysis.  NEB appeared in the profiles of all the 
samples of controls and samples of patients with OCa and CCa but faintly appeared in 
samples of patients with ECa.  At the same time, CLU consistently appeared in the 
profiles of all samples of the patients with OCa.  Figure 3.5 shows the typical O-
glycosylated urinary glycoproteome profiles for controls and patients with ECa, OCa 
and CCa. 
 
3.6.2 Image analysis of CGB lectin interacted 2-DE urinary glycoprotein profile 
The O-glycosylated urinary glycoproteome profiles of controls and patients with 
ECa were subjected to image analysis with Image Master 7.0 Platinum and statistical 
analysis.  The analysis showed a 51 kDa protein spot, known as NEB, was significantly 
different with 10.6-fold higher in the controls compared to patients with ECa.   Similar 
analysis was performed on the O-glycosylated urinary glycoproteome profiles of 
patients with OCa.  Higher levels of LRG and CLU were observed in all samples of 
patients with OCa, although the proteins were earlier reported to not to be differentially 
expressed from a previous proteomic study (Abdul-Soheimi et al., 2010).  Nevertheless, 
low levels of KNG detected in the urine of OCa patients was confirmed.  Table 3.3 
shows the relative level of NEB, LRG, CLU and KNG.  On the other hand, no 
significant changes were observed in O-glycosylated urinary glycoproteome profiles 
from patients with CCa when their level was compared to that of the controls.  Figure 
3.6 shows the mean percentage of volume contribution of CGB lectin detected urinary 
glycoproteins from controls and patients with ECa, OCa and CCa. 
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Figure 3.5: Typical O-glycosylated urinary glycoproteome profiles 
Panels A, B, C and D refer to typical O-glycosylated urinary glycoproteome profiles of 
the control, patients with ECa, OCa and CCa, respectively. The labeled protein clusters  
refer to proteins which were consistently detected by CGB lectin using Western 
Blotting approach. * indicates proteins with intensity which were significantly different 
relative to that of control. Acidic side of the membrane is to the left and relative 
molecular mass declines from the top. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
89 
 
 
A: Control 
 
 
 
 
 
 
 
 
B: ECa 
 
 
 
 
 
 
 
 
HPX 
HPX 
IGHA1 
IGHA1 
   KNG 
   KNG 
  LRG 
  LRG 
NEB 
NEB* 
       CLU 
       CLU 
 ITIH4 
 ITIH4 
 AMBP 
 AMBP 
TAGLN 
TAGLN 
HSPG2 
HSPG2 
20kDa 
20kDa 
100kDa 
100kDa 
      pH 6.5 
pH 6.5 
pH 4.5 
pH 4.5 
Results 
90 
 
 
C: OCa 
 
 
  D: CCa 
 
 
 
 
HPX 
HPX 
IGHA1 
IGHA1 
   KNG* 
   KNG 
  LRG* 
  LRG 
NEB 
NEB 
          CLU* 
       CLU 
 ITIH4 
 ITIH4 
 AMBP 
 AMBP 
TAGLN 
TAGLN 
HSPG2 
HSPG2 
pH 4.5       pH 6.5 
100kDa 
20kDa 
pH 4.5 pH 6.5 
100kDa 
20kDa 
Results 
 
 
 
 
 
Figure 3.6: Mean percentage of volume contribution of CGB lectin detected 
urinary glycoproteins from controls and patients with ECa, OCa and CCa 
The percentages of volume contribution of each urinary glycoproteins for control 
(n=11), ECa (n=7), OCa (n=9) and CCa (n=8) were calculated using Image Master 2D 
Platinum Software 7.0.  The values are expressed as mean of the percentages of volume 
contribution ± S.E.M.  Student t-test was used to analyze the significance of difference 
between controls and the patients. False discovery rate was performed using the method 
of Benjamini and Hochberg. Proteins marked with * were significantly different 
compared to that of control.  X-axis represents the sample group and Y-axis represents 
the percentage of volume contribution.   
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Table 3.3: The relative level of O-glycosylated urinary glycoprotein 
O-glycosylated 
urinary 
glycoprotein 
Fold changes 
ECa OCa CCa 
KNG n.s -6.19 n.s 
NEB -10.59 n.s n.s 
LRG n.s +17.17 n.s 
CLU n.s +17.34 n.s 
     Fold changes were relative to that of control 
     (-) decrease in level; (+) increase in level 
     n.s: not significant 
 
3.6.3  CMB lectin detected 2-DE urinary glycoprotein profile 
           When 2-DE separated urinary proteins from samples of controls were probed 
with enzyme-conjugated CMB lectin, different profiles consisting of exclusively N-
glycosylated urinary proteins were obtained.  The CMB lectin interacted urinary 
glycoproteins profiles were entirely different from those generated using the CGB 
lectin.  More spots were apparently detected by the CMB lectin detection method.  The 
N-glycosylated urinary proteins were initially identified by comparison with the earlier 
established 2-DE silver-stained urinary profiles (Section 3.5.1) as well as published 2-
DE urinary proteome (Candiano et al., 2010).  The N-glycosylated urinary proteins that 
consistently appeared in the 2-DE profiles of the controls were HPX, AAG, ZAG, 
IGHA1, KNG, ITIH4, AMBG, HSPG2,TAGLN, apolipoprotein D (APOD) and retinol 
binding protein 4 (RBP4). 
 
          When the analysis was performed on the 2-DE separated urinary proteins from 
patients with ECa, OCa and CCa who were newly diagnosed and untreated, similar N-
glycosylated urinary protein profiles were obtained, with the exception of several 
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protein spots.  LRG and haptoglobin β chain (HPβ) were consistently detected in all 
CMB blots of the OCa patients and a considerable number of CMB blots of patients 
with CCa (n=4) and ECa (n=5).  Like the previous CGB blots, the CMB blot also 
unmasked CLU, which could not be detected in the 2-DE silver-stained urinary profiles.  
Figure 3.7 shows the typical N-glycosylated urinary protein profiles for controls and 
patients with ECa, OCa and CCa. 
 
3.6.4  Image analysis of CMB lectin interacted 2-DE urinary glycoprotein profile 
           When the N-glycosylated urinary glycoproteins profiles of controls and patients 
with ECa were scanned and subjected to image analysis using Image Master Platinum 
7.0 software, higher levels of AAG and ZAG were detected in the patients.  This data 
provides confirmation of the differential levels of the proteins that was earlier 
established in patients with ECa using the silver-staining approach (Section 3.5.1). 
 
           A similar comparative analysis conducted on the CMB lectin blots from patients 
with OCa and controls also revealed the overexpression of urinary AAG and ZAG in 
the patients.  In addition to these two protein clusters, LRG, HPβ and CLU were also 
demonstrated to be enhanced in the CMB lectin blots from patients with OCa.  
However, an earlier work by silver staining performed on patients with OCa had 
reported that these urinary glycoproteins were found not significantly different relative 
to the controls (Abdullah-Soheimi et al., 2010).  On the other hand, the significantly 
low level of urinary KNG detected in the patients with OCa was validated in this study. 
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Figure 3.7: Typical N-glycosylated urinary glycoproteome profiles 
Panels A, B, C and D refer to typical N-glycosylated urinary glycoproteome profiles of 
the control, patients with ECa, OCa and CCa, respectively The labeled protein clusters  
refer to proteins which were consistently detected by CMB lectin. * indicates proteins 
with intensity which were significantly different relative to that of control. Acidic side 
of the membrane is to the left and relative molecular mass declines from the top. 
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Table 3.4 shows the relative level of CMB lectin detected urinary glycoproteins in the 
three groups of cancer patients studied.          
 
When image analysis was performed on the CMB blots from patients with CCa 
as well as those of the controls, there was no significant difference between the level of 
all detected urinary glycoproteins.  Figure 3.8 shows the mean percentage of volume 
contribution of CMB lectin detected urinary glycoproteins from the controls and 
patients with ECa, OCa and CCa.       
 
Table 3.4: The relative level of N-glycosylated urinary glycoprotein 
N-glycosylated 
urinary glycoprotein 
Fold of changes 
ECa OCa CCa 
KNG n.s. 3.29 n.s. 
LRG n.s. +6.07 n.s. 
HPβ n.s. +63.33 n.s. 
ZAG +2.79 +4.05 n.s. 
AAG +31.8 +58.23 n.s. 
CLU 
n.s. 
+5.20 n.s. 
Fold changes were relative to that of control 
(-) decrease in level; (+) increase in level 
n.s.: not significant 
 
3.7  Identification of urinary proteins using mass spectrometry 
  Mass spectrometry analysis was performed using the 4800 Plus MALDI 
TOF/TOF analyzer (Applied Biosystem/MDS Sciex, Toronto, Canada).  The 
experimental peptide masses were then submitted to the MASCOT database to search 
  
 
 
 
 
Figure 3.8: Mean percentage of volume contribution of CMB lectin detected 
urinary glycoproteins from controls and patients with ECa, OCa and CCa 
Percentage of volume contribution of each urinary glycoproteins for control (n=11), 
ECa (n=7), OCa (n=9) and CCa (n=8) was calculated using Image Master 2D Platinum 
Software 7.0.  The value was expressed as mean of the percentages of volume 
contribution ± S.E.M.   Student t-test was used to analyze the significant difference 
between the control and the patients. False discovery rate was performed using the 
method of Benjamini and Hochberg. Proteins marked with * were significantly different 
compared to that of control.  X-axis represents the sample group and Y-axis represents 
the percentage of volume contribution.   
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against known theoretical peptide masses of proteins from Homo sapiens.  Database 
search parameters were set as: the enzyme trypsin was used; one missed cleavage was 
allowed in trypsin digestion; variable modification included were carbamidomethylation 
of cysteine and oxidation of methionine; the mass tolerance for MS precursor ion and 
MS/MS fragment ion were 50 ppm and 0.1 Da, respectively; and only monoisotopic 
masses were included in the search.  The identification of protein clusters that 
consistently appeared in 2-DE silver-stained profiles was done by subjecting the spot 
clusters of urine proteins to in-gel digestion, followed by the analysis with the mass 
spectrometry and database search.  The identities of these protein clusters were 
confirmed as KNG, AAG, ZAG, CD59, AMBP, IGHG3 and KAC.  
 
          For protein clusters that did not appear by silver staining but only detected using 
lectins, on membrane digestion (Section 2.2.7.2) was performed prior to the analysis by 
mass spectrometry.  NEB and CLU were successfully identified using this technique.  
Table 3.5 shows the mass spectrometric identification data of the urinary proteins that 
were resolved by 2-DE and using silver staining, CGB lectin and CMB lectin for 
detection.  The HP cluster spots detected on the CMB blot was actually the β chain of 
protein.  The mass spectrometry analysis generated peptides sequences with high 
confidence which spanned within the β chain region of HP.  Table 3.6 shows the list of 
matched peptide sequences with high confidence for HP.  On the other hand, NEB was 
suggested to be a truncated fragment of its native form due to the large discrepancy 
presented between its experimental mass and theoretical mass.     
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Table 3.5: Mass spectrometric identification of 2-DE resolved urinary proteins 
Protein 
Entry 
Name
+
 
Protein name Accession 
number
# 
Nominal 
mass 
(kDa)/pI  
MOWSE 
protein 
score 
Sequence 
coverage 
(%) 
NEB* 
CLU* 
KNG 
Nebulin 
Clusterin 
Kininogen 
P20929 
P10909 
P01042 
775/9.11 
52/5.89 
71/6.34 
64 
25 
68 
1
#
 
11 
7 
IGHG3 Ig 3 chain C region P01860 41/8.46 16 3 
AAG α1-acid glycoprotein  P19652 23/5.03 241 16 
ZAG Zinc α2 glycoprotein P25311 33/5.57 134 20 
AMBP Protein AMBP P02760 39/5.95 50 12 
IGKC Ig 1 chain C region P01834 11/5.58 141 32 
CD59 
HP 
LRG 
 
  ITIH4         
CD59 glycoprotein 
Haptoglobin 
Leucine-rich α2 
glycoprotein 
Inter alpha trypsin 
inhibitor heavy chain H4  
P13987 
P00738 
P02750 
 
Q14624 
14/6.02 
45/6.13 
38/6.45 
 
103/6.51 
121 
313 
149 
 
336 
 
18 
18 
10 
 
14 
*The protein was prepared by on-membrane digestion 
#
Relative to the sequence of native nebulin 
 
+
Protein entry names are from the UniProtKB database http://www.uniprot.org assessed 
on 22 Feb 2012 
Accession numbers are from the Mascot search engine  
 
Table 3.6: The list of matched peptide sequences with high confidence for 
haptoglobin 
Peptide sequence Amino acid 
R.VGYVSGWGR.N 278-286 
K.YVMLPVADQDQCIR.H 298-311 
K.SPVGVQPILNEHTFCAGMSK.Y 326-345 
K.YQEDTCYGDAGSAFAVHDLEEDTWYATGILSFDK.S 346-379 
Sequences of peptides were checked using the Swiss-Prot database. 
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3.8   LC-MS/MS analysis of lectin affinity captured urinary glycoproteins 
3.8.1  CGB lectin affinity chromatography 
            To analyse native O-glycosylated proteins, 400 μg of pooled urinary protein 
samples of eleven control subjects, seven ECa patients, nine OCa patients and eight 
CCa patients were respectively subjected to the CGB lectin affinity chromatography as 
described in Section 2.2.8.2.  The columns were washed extensively with PBS at pH 7.2 
to remove non-binding proteins and other substances.  Fractions of 1 ml were collected 
and monitored at 280 nm until the absorbance reached the baseline.  Bound O-
glycosylated urinary proteins were eluted with 0.1 M melibiose.  Figure 3.9 shows the 
elution profiles of the bound fractions of CGB lectin affinity chromatography for 
controls and the three groups of cancer patients. 
 
3.8.2   CMB lectin affinity chromatography       
            Native N-glycosylated urinary proteins were also analysed using the CMB lectin 
affinity chromatography as described in Section 2.2.8.2.  Similar to the CGB 
chromatography fractionation procedure, pooled urine samples of the controls, ECa 
patients, OCa patients and CCa patients were respectively loaded into separate CMB 
affinity columns and washed extensively with PBS.  Fractions of 1 ml were collected 
and monitored at 280 nm until the absorbance level reached the baseline.  The bound N-
glycosylated urinary proteins were eluted with 0.1 M methyl-α-D-mannopyranoside. 
Figure 3.10 shows the elution profiles of the bound fractions of CMB lectin affinity 
chromatography for the controls and three groups of cancer patients.
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Figure 3.9: Elution profiles of bound fractions of CGB lectin affinity 
chromatography 
Each pooled urine samples were subjected to the CGB lectin affinity column 
chromatography. Unbound fractions were washed out with PBS, pH 7.2 until the 
absorbance reached the baseline. Bound glycoproteins were eluted out with 0.1 M 
melibiose with gravitational flow. Four different elution profiles of controls (panel A), 
and patients with ECa (panel B), OCa (panel C) and CCa (panel D) were generated. 
Arrow indicates the start of sugar elution. 
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C: OCa 
 
 
D: CCa 
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Figure 3.10: Elution profiles of bound fractions of CMB lectin affinity 
chromatography  
Each pooled urine samples were loaded into the CMB lectin affinity column and 1 ml of 
fractions were collected. Unbound fractions were washed out with PBS, pH 7.2 until  
absorbance fell to the baseline. Elution of bound glycoproteins were carried out using 
0.1 M methyl-α-D-mannopyranoside. Four different elution profiles of control (panel 
A), and patients with ECa (panel B), OCa (panel C) and CCa (panel D) were generated. 
Arrow indicates the start of sugar elution.  
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3.8.3   Profiling of native O-glycosylated urinary proteins captured by CGB lectin 
           Profiling of native O-glycosylated urinary proteins was performed by subjecting 
the bound protein fractions of each groups of the immobilized CGB-lectin affinity 
chromatography to LC-MS/MS analysis separately.  In this study, a total of 36 proteins 
were identified with high confidence levels.  Out of the 36 identified proteins, ten were 
annotated as O-glycosylated by the Swiss-Prot database.  Another 26 were annotated as 
potential O-glycosylated urinary proteins as predicted by the NetOGlyc 3.1 server.  The 
O-glycosylated urinary proteins were categorized based on their subcellular localization.  
Based on the Swiss-Prot database, there were 11 secreted proteins, 15 membrane 
proteins, four nuclear proteins, four cytoplasmic proteins and two unknown proteins.  
Table 3.7 summarizes all of the identified O-glycosylated proteins or potential O-
glycosylated proteins that were captured by the CGB  lectin affinity column 
chromatography. 
 
Table 3.7: List of O-glycosylated/potentially O-glycosylated proteins isolated using 
CGB lectin 
Protein name Accession 
number 
Subcellular 
location 
Glycan# 
Protein AMBP P02760 Secreted O-linked 
ATP synthase subunit  beta, 
mitochondrial 
P24539 Membrane Potential O-linked 
Serotransferrin P02787 Secreted O-linked  
Transmembrane protein 110 Q86TLZ Membrane Potential O-linked 
Phosphoinositide-3 kinase interacting 
protein 1 
Q96FE7 Membrane O-linked 
Ribonuclease pancreatic P07998 Secreted Potential O-linked 
Prostaglandin-H2-D isomerase P41222 Secreted Potential O-linked 
Membrane bound transcription factor 
site-1 protease 
Q14703 Membrane Potential O-linked 
Homeobox protein engrailed 2 P19622 Nucleus Potential O-linked 
Actin, cytoplasmic 1 P60709 Cytoplasmic Potential O-linked 
Neurofilament medium polypeptide P07197 Cytoplasmic O-linked 
    
            Continue on next page. 
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                     Continuation from previous page. 
    
CD55 decay-accelerating factor 
splicing variant 4 
Q14UF3 Membrane Potential O-linked 
Leucine rich alpha 2 glycoprotein P02750 Secreted O-linked 
Spondin-2 Q9BUD6 Secreted Potential O-linked 
Protein RRP5 homolog Q14690 Nucleus Potential O-linked 
CD44 antigen P16070 Membrane O-linked 
Phosphatidylinositol-3,4,5-triphosphate 
5-phosphatase-1 
Q92835 Membrane Potential O-linked 
Solute carrier family 12 member 6 Q9UHW9 Membrane Potential O-linked 
Mucin-5B Q9HC84 Secreted O-linked 
Major facilitator superfamily domain 
containing protein 10 
Q14728 Membrane Potential O-linked 
PDZ and LIM domain protein 5 Q96HC4 Membrane  Potential O-linked 
Leukocyte associated immunoglobulin-
like receptor 1 
Q6GTX8 Membrane Potential O-linked 
Tumor necrosis receptor superfamily 
member 16 
P08138 Membrane Potential O-linked 
Lipocalin-1 P31025 Secreted Potential O-linked 
Amyloid beta A4 P05067 Membrane O-linked 
Nebulin P20929 Cytoplasmic Potential O-linked 
Transcription factor HES-2 Q9Y543 Nucleus Potential O-linked 
Rho GTPase-activating protein 12 P20936 Cytoplasmic Potential O-linked 
Solute carrier family 13 member 3 Q8WWT9 Membrane Potential O-linked 
Sodium/bile acid contransporter Q14973 Membrane Potential O-linked 
Bromodomain-containing protein 3 Q15059 Nucleus Potential O-linked 
Inter alpha trypsin inhibitor heavy 
chain H4 
Q14624 Secreted O-linked 
Ig gamma-1 chain C region P01857 Secreted Potential O-linked 
Ig gamma-2 chain C region P01859 Secreted Potential O-linked 
Ig alpha-1 chain C region P01876 Unknown O-linked 
Ig lambda-1 chain C region  P0CG04 Unknown Potential O-linked 
# Type of glycan was annotated by UniProt; glycosylation potential was determined by 
NetOGlyc 3.1 (http://www.cbs.dtu.dk/services/NetOGlyc). 
 
 
3.8.4   Profiling of native N-glycosylated urinary proteins captured by CMB lectin 
          Profiling of native N-glycosylated proteins of controls and patients with ECa, 
OCa and CCa were performed by subjecting pooled urine samples from controls and 
patients to immobilized CMB lectin affinity chromatography separately and analysis of 
their bound fractions using LC-MS/MS.  Out of the 46 identified proteins with high 
confidence level, 28 were annotated as proteins that are N-glycosylated by the Swiss-
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Prot database.  Another 18 were annotated as potential N-glycosylated proteins, as 
predicted by the NetNGlyc 1.0.  Based on the Swiss-Prot database, 17 were secreted 
proteins, 14 were membrane proteins, 5 were nuclear proteins, 5 were cytoplasmic 
proteins, 1 was lysosomal protein, 1 was endoplasmic reticulum protein, 1 was 
mitochondrion protein and 2 were unknown proteins.  Table 3.8 summarizes all of the 
identified N-linked glycoprotein or potential N-linked glycoproteins captured by CMB- 
lectin affinity column chromatography.  
 
Table 3.8: List of N-glycosylated/potentially N-glycosylated proteins isolated using 
CMB lectin 
Protein name Accession 
number 
Subcellular 
location 
Glycan# 
Protein AMBP P02760 Secreted N-linked 
Zinc alpha-2 glycoprotein P02768 Secreted N-linked 
Serotransferrin P02787 Secreted N-linked 
Uromodulin P07911 Secreted N-linked 
Transmembrane protein 110 Q86TL2 Membrane  Potential N-linked 
Transmembrane protein 43 Q9BTV4 Nucleus Potential N-linked 
Phosphoinositide-3-kinase interacting 
protein 1 
Q96FE7 Membrane N-linked 
Alpha 1-acid glycoprotein P19652 Secreted N-linked 
Ig kappa chain C region  P01834 Unknown Not N-linked 
LRP11 protein Q96A73 Unknown Not N-linked 
E3 ubiquitin-protein ligase RNF149 Q8NC42 Membrane  N-linked 
Ribonuclease pancreatic P07998 Secreted N-linked 
Prostaglandin-H2 D-isomerase P41222 Secreted N-linked 
Membrane bound transcription factor 
site-1 protease 
Q14703 Membrane N-linked 
RecQ-mediated genome instability 
protein 1 
Q9H9A7 Nucleus Potential N-linked 
G protein coupled receptor 87 Q9BY21 Membrane N-linked 
Homeobox protein engrailed-2 P19622 Nucleus Potential N-linked 
Ig alpha-1 chain C region P01876 Unknown N-linked 
Non-secretory ribonuclease P10153 Cytoplasmic N-linked 
CD44  antigen P16070 Membrane N-linked 
Galectin-3 binding protein P17931 Secreted Potential N-linked 
Grainyhead-like protein 1 homolog  Q9NZ15 Nucleus Potential N-linked 
WAP four-disulfide core domain 
protein 2 
Q14508 Secreted N-linked 
                        Continue on next page. 
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CD59 glycoprotein P13987 Secreted N-linked 
Kininogen P01042 Secreted N-linked 
Hemopexin P02790 Secreted N-linked 
Granulins P28799 Secreted N-linked 
N-acetylglucosamine 6-sulfatase P15586 Lysosome N-linked 
Lysosome associated membrane 
glycoprotein 2 
P13473 Membrane N-linked 
Coiled- coil domain containing protein 
125 
Q86Z20 Cytoplasmic  Potential N-linked 
ATrich interactive domain containing 
protein 4B 
Q4LE39 Cytoplasmic Potential N-linked 
Basement membrane specific heparin 
sulfate proteoglycan core protein 
P98160 Secreted N-linked 
Symplekin Q92797 Cytoplasmic Potential N-linked 
Collagen-3 (VI) chain Q01955 Secreted N-linked 
MAGUK p55 subfamily member 7 Q5T2T1 Nucleus Potential N-linked 
Ran binding protein 17 Q9H2T7 Membrane  N-linked 
Propionyl-CoA carboxylase alpha 
chain, mitochondrion 
P05165 Mitochondrion Potential N-linked 
PGAP2-interacting protein Q9H720 Membrane N-linked 
Prostaglandin F2 receptor negative 
regulator 
P41222 Secreted N-linked 
Growth hormone receptor P10912 Membrane N-linked 
Serine/threonine kinase 11 interacting 
protein 
Q8N1F8 Cytoplasmic Potential N-linked 
Probable phospholipid transporting 
ATPase IIA  
O75110 Membrane Potential N-linked 
Solute carrier family 26 member 9 Q8BU91 Membrane Potential N-linked 
ATP binding cassette subfamily B 
member 10, mitochondrion 
Q9NRK6  Membrane  Potential N-linked 
Rab II family interacting protein 1 Q6WKZ4 Membrane Potential N-linked 
Protein disulfide-isomerase A2 Q13087 Endoplasmic 
reticulum 
N-linked 
# Type of glycan was annotated by UniProt; glycosylation potential was determined by 
NetNGlyc 1.0 (http://www.cbs.dtu.dk/services/NetNGlyc/)  
 
 
3.8.5  Protein quantification using spectral counting 
          To validate the altered levels of the urinary proteins that were shown by 2-DE 
and Western blot-lectin analyses, proteins that were subjected to LC-MS/MS analysis 
(i.e., KNG, AAG, ZAG, CD59, LRG and NEB) were further analyzed using spectral 
counting approach.  The technique involves relative protein quantification based on the 
normalized spectral abundance factor (NSAF) values that were generated from the 
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number of identified MS/MS spectra of a protein and its peptide length.  Among the 
proteins that were analysed, only  LRG and NEB were O-glycosylated.  Analysis of the 
NSAF values of LRG appears to indicate that its concentration was higher in patients 
with OCa compared to the controls, where else the concentrations of urinary LRG of 
patients with ECa and CCa were comparable to the controls.  On the other hand, the 
NEB peptide spectrum with the de novo sequence 
K.AYELQSDNVYKADLEWLRGIGWMPNDSVSVNHA.K (amino positions 4103-
4136) was apparently present only in the pooled urine samples of the controls but not 
detected in the pooled urine samples of patients with ECa.  
 
Based on the spectral count of bound fractions from CMB lectin affinity 
chromatography, the concentrations of ZAG and AAG were found to be higher in the 
pooled urine samples from patients with ECa.  Apart from that, the concentration of 
KNG was lower in bound fractions of CMB-lectin affinity columns from patients with 
OCa.  Eleven spectrums for HP were solely present in the urine samples from patients 
with OCa when their pooled bound fractions of CMB lectin affinity columns were 
analyzed.  Similar to NEB, two CD59 peptide spectrums with the de novo sequence 
K.FEHCNFNDVTTR.L (amino position 67-78) appeared only in the pooled urine 
samples of controls but not in the pooled urine samples of all cohorts of patients.  Table 
3.9 summarizes the number of spectra and the ratio of the altered proteins which were 
previously detected to be significantly different in 2-DE and Western blot-lectin 
analysis.   
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Table 3.9: The number of spectra of differentially expressed urinary proteins 
obtained from 2-DE silver-stained analysis and Western blot-lectin analysis 
 Number of spectra of O-
glycosylated urinary proteins 
 
 
 
 
 
 
Number of spectra of N-glycosylated 
urinary proteins 
Protein Control ECa OCa CCa Control ECa OCa CCa 
KNG - - - - 4 3 1 3 
AAG - - - - 6 11 4 5 
ZAG - - - - 19 38 13 16 
LRG 8 9 29 10 - - - - 
NEB 1 - 1 1 - - - - 
CD59 - - - - 2 - - - 
HP - - - - - - 11 - 
  -: not detected 
 
3.9  Competitive ELISA 
            Since CLU was not detected in both CGB and CMB lectins bound fractions, 
competitive ELISA was performed using monoclonal antisera against CLU to validate 
the altered levels of the urinary proteins that were detected in the patients with OCa (n 
= 9) compared to the control subjects (n = 11). Figure 3.11 demonstrates the mean 
percentage of inhibition of CLU that was tested in respective groups of samples. The 
expression of CLU was significantly enhanced in almost all of the urine samples of the 
OCa patients compared to the controls.  
 
3.10  SELDI-TOF-MS analysis of urinary glycopeptides 
     In this study, a preliminary investigation was performed to determine if the 
CMB and CGB lectins may be used to discriminate digested gycopeptides that are 
present in the urine of patients with ECa, CCa and OCa, compared to the controls using 
the SELDI-TOF-MS.  The SELDI-TOF-MS is restricted to the analysis of low 
molecular weight peptide.  Thus, subsequent analysis of urinary proteins from controls 
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Figure 3.11: Estimation of CLU using competitive ELISA 
Urinary proteins from controls and patients with OCa were incubated with anti-CLU 
monoclonal antibody in microplate wells. The amount of CLU present in the samples 
was proportional to the percentage of inhibition. * denotes the percentage of inhibition 
was  statistically significant with p< 0.05.   
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and patients, as described in the following section, initially involved the preparation of 
peptides from the urinary protein samples using trypsin digestion.  This was followed 
by selective capture of the N- or O-glycopeptides using the respective CMB and CGB 
lectins that were immobilised onto the PS10 chips (Section 3.10.1).  Profiling of the 
glycopeptides was performed by detection and alignment of the peaks and analysis of 
the data generated using a decision tree algorithm (Section 3.10.2-3).  Potential peaks 
that can truly discriminate between each groups of samples were finally identified 
(Section 3.10.4).     
 
3.10.1  Detection of peptide peaks 
           From the SELDI spectra of the CMB and CGB lectin captured urinary 
glycopeptide profiles, a total of 54 and 24 raw peaks were detected between m/z 1000 
and 10000, respectively.  Figure 3.12 shows the representative spectra views for the 
CMB and CGB lectin captured urinary glycopeptides of controls and patients with ECa 
CCa and OCa, respectively. 
 
3.10.2 Identification of potential biomarker pattern and construction of Diagnostic 
Model of CMB lectin captured urinary glycopeptide profile 
           When comparison between the CMB lectin captured urinary glycopeptides of 
controls and patients with ECa, OCa and CCa were performed, two peaks (m/z 1201 and 
1449) were selected by the Biomarker Pattern Software 5.0 to set up the decision tree 
for group discrimination.  Figure 3.13 shows the tree structure and the sample 
distribution for these peaks in the CMB lectin captured urinary glycopeptide profile.  At 
node 1, m/z 1201 was used to classify the samples, where samples having the peak 
Results 
 
 
 
 
 
 
Figure 3.12: Representative spectral view of CMB and CGB lectin captured 
urinary glycopeptides 
Urinary peptides were incubated on lectins immobilized PS10 chips and subjected to 
SELDI-TOF analysis. N-linked or O-linked glycopeptides captured by CMB (panel A) 
or CGB lectin (panel B), respectively were ionized by laser energy and measured as m/z 
(y-axis) by the ion chamber of the instrument. The detected urinary glycopeptides are 
expressed as a series of peaks with their own intensity, μA (y-axis).      
 
 
 
 
 
 
 
 
 
 
Results 
112 
 
 
 
A 
 
B 
 
 
 
 
 
Control 
ECa 
CCa 
OCa 
Control 
ECa 
CCa 
OCa 
Results 
 
 
 
 
 
 
Figure 3.13: Tree structure profiles and samples distribution of CMB lectin 
captured urinary glycopeptides 
Peaks with m/z of 1201 and 1449 were chosen to set up the decision tree. C, E, N and O 
refer to CCa, ECa, control and OCa accordingly. The root node and the terminal node 
were indicated as blue and red colours, respectively.  
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intensity higher than 91.783 μA went to Terminal node 3.  All four samples of OCa 
went into this node.  The rest of the samples entered Node 2, which had four samples 
each for the remaining groups.  At node 2, samples having m/z 1449 with peak intensity 
higher than 94.606 μA went to Terminal node 2.  One sample of CCa and four samples 
of ECa fell into this node.  The remaining samples entered Terminal node 1 with three 
samples of CCa and four samples of controls.  
 
3.10.3  Identification of potential biomarker pattern and construction of Diagnostic 
Model of CGB lectin captured urinary glycopeptide profile 
            Two peaks, m/z 3656 and 2138 from CGB lectin captured urinary glycopeptides 
profile were chosen to set up the decision tree by the Biomarker Pattern Software 5.0 for 
group discrimination.  Figure 3.14 shows the tree structure and the sample distribution 
for these peaks in the CGB lectin captured urinary glycopeptide profile.  Samples 
having m/z 3656 with peak intensity lower than 1.052 μA went to Terminal node 1.  At 
this node, four samples of ECa and two samples of OCa were selected.  The remaining 
samples entered Node 2, which comprised four samples each of control and CCa, and 
two samples for OCa.  At node 2, samples were divided based on m/z 2138, where 
samples with peak intensity higher than 7.667 μA went to Terminal node 3.  Four 
samples of CCa and two samples of control fell into this terminal node.  The remaining 
samples entered Terminal node 2, which were two samples each  of  control and OCa. 
 
3.10.4  Statistical analysis of protein peaks that discriminate the groups 
           The significance of the peaks that discriminated each of the groups based on the 
decision tree constructed from the CMB lectin captured urinary glycopeptides profiles 
Results 
 
 
 
 
 
 
Figure 3.14: Tree structure profiles and samples distribution of CGB lectin 
captured urinary glycopeptides 
Peaks with m/z of 2138 and 3656 were chosen to set up the decision tree. C, E, N and O 
refer to CCa, ECa, control and OCa, accordingly. The root node and the terminal node 
were indicated as blue and red colour, respectively.  
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was determined with EDM program.  The peaks m/z 1201 and 1449 obtained from 
CMB lectin captured urinary glycopeptides were significantly different when compared 
between groups with the p-value of 0.028.  Figure 3.15 shows the representative 
spectral view of m/z 1201 and 1449 for the CMB lectin urinary glycopeptides profiles 
for controls and the cancer groups.  Both proteins were overexpressed in all groups of 
cancers relative to the controls.  Indeed, the mean peak intensity of m/z 1201 and 1449 
in OCa samples were 137.034±17.399 μA and 164.353±15.821 μA, respectively, which 
were higher than the other two cancer cohorts. Table 3.10 shows the mean peak 
intensity of m/z 1201 and 1449 captured by the CMB lectin chip.         
 
           Similar statistical analysis was conducted for the CGB lectin captured urinary 
glycopeptides for the peak m/z 2198 and 3656.  Figure 3.16 shows the spectral view of 
the peaks.  However, both peaks were not significantly different between each of the 
groups (p>0.05).  The mean peak intensity of both peaks were higher in the controls 
compared to the other three cancer groups, with the value of 4.884±3.207 μA and 
13.849±7.413 μA, respectively.  Table 3.11 shows the mean peak intensity of m/z 2198 
and 3656. 
 
Table 3.10: Mean peak intensity for m/z 1201 and 1449 captured by CMB lectin 
chip 
m/z 
Mean peak intensity (μA) 
Control ECa CCa OCa 
1201 24.601±12.102 31.018±4.263 36.284±16.459 137.034±17.399 
1449 59.299±15.740 118.036±10.443 98.098±31.132 164.353±15.821 
All values were expressed as mean±S.E.M 
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Figure 3.15: Representative spectral view of m/z 1201 and 1449 for the CMB lectin 
urinary glycopeptides profiles for control and the cancer groups 
Peaks with m/z 1201 and 1449 were selected to construct the decision tree and thus 
subjected to the statistical analysis with Expression Difference Mapping. Both peaks 
were significantly different between each groups. The x axis represents m/z values and y 
axis represents relative intensity in μA.   
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Figure 3.16: Representative spectral view of m/z 2138 and 3656 for the CGB lectin 
urinary glycopeptides profiles for control and the cancer groups 
Peaks with m/z 2138 and 3656 were used to set up the decision tree even though they 
were not statistically significant when compared between the four groups. The x axis 
represents m/z values and y axis represents relative intensity in μA. 
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Table 3.11: Mean peak intensity for m/z 2138 and 3656 captured by CGB lectin 
chip 
m/z 
Mean peak intensity (μA) 
Control ECa CCa OCa 
2138 13.849±7.413 7.597±2.653 12.628±2.795 5.529±3.065 
3656 4.884±3.207 0.624±0.207 2.046±0.387 1.151±0.647 
All values were expressed as mean±S.E.M 
 
3.10.5 Sensitivity and specificity determination for the decision tree 
           A total of 16 samples with four samples from each group (controls and 3 cohort 
cancer patients) were used to evaluate the sensitivity and the specificity of the peak in 
discriminating the cohorts from each other.   Based on the figure 3.15, two peaks with 
m/z of 1201 and 1449 were used to set up the decision tree for CMB lectin captured 
urinary glycopeptides.  All ECa samples were correctly classified and 11 out of 12 non 
ECa samples were correctly classified.  This result yielded a sensitivity of 100% and a 
specificity of 91.67%.  On the other hand, the sensitivity and the specificity for OCa 
was 100% when all OCa samples were successfully classified and no samples for other 
cohorts were misclassified as OCa.  Unlike ECa and OCa samples, decision tree was not 
able to classify the CCa since all CCa samples were grouped in the decision nodes. 
Table 3.12 shows the sensitivity and the specificity of each cohort in CMB lectin 
captured urinary glycopeptides.   As shown in Figure 3.16, two peaks with m/z 2138 and 
3656 were used to set up the decision tree for CGB lectin captured urinary 
glycopeptides.  Based on the decision tree, all samples of ECa and CCa were classified 
as their own group, which yielded a sensitivity of 100% for each of them.  However, 
their specificity were only 83.33% when two samples of non specified samples were 
misclassified into their group.  Besides, the decision tree could not classify OCa 
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samples where all decision nodes and terminal nodes were not able to specify OCa 
samples.  Table 3.13 shows the sensitivity and the specificity of each cohort in CGB 
lectin captured urinary glycopeptides.  
 
Table 3.12: Sensitivity and specificity of CMB lectin to discriminate urinary 
glycopeptides from patients with cancers using the SELDI-TOF-MS chip based 
assay 
 
Sample Cases 
Number of 
correctly 
classified 
samples* 
Classification 
accuracy (%) 
ECa 4 4 100
a 
Non-ECa 12 11 91.67
b 
    
CCa - - - 
Non-CCa - - - 
    
OCa 4 4 100
a 
Non-OCa 12 12 100
b 
*Determined from the decision tree of CMB lectin captured 
urinary glycopeptides 
- Not applicable   
a
 Sensitivity   
b
 Specificity 
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Table 3.13: Sensitivity and specificity of CGB lectin to dicriminate urinary 
glycopeptides from patients with cancers using the SELDI-TOF-MS chip based 
assay  
 
Sample Cases 
Number of 
correctly 
classified 
samples* 
Classification 
accuracy (%) 
ECa 4 4 100
a 
Non-ECa 12 10 83.33
b 
    
CCa 4 4 100
a 
Non-CCa 12 10 83.33
b
 
    
OCa - - - 
Non-OCa - - - 
* Determined from the decision tree of CGB lectin captured 
urinary glycopeptides 
- Not applicable   
a
 Sensitivity  
 
b
 Specificity 
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CHAPTER 4:  DISCUSSION 
 
4.1  Collection and processing of urine samples 
           The procedures for collection and processing of the urine samples are important 
before a proteomic analysis because they may affect the results.  Hence, several 
precautions were taken in the collection and processing steps.  The morning midstream 
urine was chosen to be collected for the analyses instead of the first voided urine 
because it provides consistent protein content for profiling and characterization 
(Casado-Vela et al., 2011).  The addition of 20 mM sodium azide into the urine samples 
was done immediately after collection in order to prevent any bacterial and/or fungi 
growth in the urine samples.  Presence of the microorganisms can interfere with the 
subsequent proteome analysis of the urine samples.  Protease inhibitors were not added 
into the urine samples because proteases are deactivated once they are voided from the 
body (Coon et al., 2008).  Furthermore, the protease inhibitor might interfere with the 
subsequent proteome analysis.  Before further processing, urine samples were 
centrifuged at 10000 × g for 15 minutes to eliminate contaminants that may be present 
in the urine, such as cells, microorganisms and debris.  Removal of the contaminants 
could eventually reduce the appearance of additional substances in the urine samples, 
which sometimes affects the quality of the results of the proteome analysis.  Subsequent 
to this, the supernatants were dialyzed against four changes of distilled water, which 
reduced the salt concentration of the urine samples, which otherwise would interfere 
with the 2-DE separation of the urinary proteins.   
 
The control of temperature during urine sample processing and storage would 
significantly influenced the results achieved for the proteome analysis.  Thus,  all urine 
sample processing procedures were done within not more than three days of storage at 
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4°C, where protein degradation was still minimal.  This was in accordance to the report 
by Schaub et al. (2004), which showed that urinary proteins were not significantly 
altered when stored up to 3 days at 4°C.  After dialysis, the urine samples were 
lyophilized to prevent degradation of the urinary protein and growth of bacteria.  Prior 
to protein analysis, the lyophilized urinary samples were stored at -80
o
C to ensure that 
the intact structure of urinary proteins was maintained for long term storage.  The 
dialysis and lyophilization of the urine sample could improve the reproducibility in term 
of variability in protein concentration caused by hydration status of each samples and 
give better resolution for its downstream analysis.   
 
The concentrations of the urinary proteins obtained from patients were estimated 
using the standard curve constructed from a range of BSA dilutions.  Generally, higher 
concentrations of urinary proteins were observed in cancer patients compared to the 
control subjects.  The excretion of abnormal amount of proteins in the urine, which is 
referred as proteinuria, more often occurs in a number of pathological conditions, 
including cancer (Rudman et al., 1978).  This is to be expected as elevated amounts of 
protein are circulated in the body and finally deposited in the kidney and excreted as 
urine during the malignancy condition (Pedersen and Milman, 1996).   In this study, 
small number of samples (control=11, ECa=7, OCa=9, CCa=8) was collected and used 
for the present gel- and lectin-based proteomic analyses because these analyses were 
tedious and expensive.  Furthermore, it was difficult to obtain sufficient number of 
samples for the study. 
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4.2  2-DE analysis of urinary proteins obtained from controls and patients with 
ECa 
          Urine is one of the body biofluids which is commonly used in clinical diagnosis.  
Unlike serum or plasma, the collection of human urine is more convenient and non-
invasive, which makes it one of the favourite choices for diagnostic purposes.  Many 
studies have been done to explore the diagnostic value of urine for detecting cancer 
(Tantipaiboonwong et al., 2005; Kreunin et al., 2007).  The search for cancer 
biomarkers from urine has gained momentum with the development of advanced 
proteomic technology.  This include the application of 2-DE and mass spectrometry.  2-
DE is a conventional method that is widely used to analyze a large number of proteins 
present in a given sample.  The usage of this method enables the quantification of 
proteins and thus provides a platform to conduct a comparative study of protein 
expression between controls and patients.  However, 2-DE has its own drawbacks such 
as difficulty to detect extremely low or high molecular weight proteins, membrane 
proteins and low abundance proteins.  The combination of 2-DE with other proteomic 
techniques such as LC-MS/MS and SELDI-TOF could enhance the sensitivity in 
analyzing a complete proteome of a given sample because different proteomic 
technologies would generate different findings.  Furthermore, their outcomes could also 
improve our understanding on the facilitation of the cancer management and therapeutic 
intervention.  
 
 In the present study, highly resolved 2-DE silver-stained urinary protein profiles 
were developed for controls and patients with ECa.  Because of the inter-variation and 
heterogeneity of protein composition for each individual, the image analysis of the 
protein clusters were restricted to those proteins that appeared consistently in all 
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individuals.  Therefore, seven protein clusters namely KNG, AAG, ZAG, CD59, 
AMBP, IG3C and IGKC were chosen for densitometry analysis. Mass spectrometry 
analysis with MALDI-TOF/TOF was performed to identify these proteins.  Analysis of 
the 2-DE silver-stained profiles of controls and patients with ECa demonstrated the 
altered expression of AAG, ZAG and CD59.  The intensity of AAG and ZAG were 
significantly higher and the expression of CD59 was much lower in patients with ECa.  
When the present data was compared to those previously reported on patients with OCa 
and CCa, it appears that ECa may be differentiated from OCa and CCa (Abdullah-
Soheimi, 2010; Mu et al.,2012) based on the different protein expression.  Each of these 
cancers seems to have their own unique urinary protein profile.    
 
The altered expression of the urinary proteins for ECa detected in the present 
study were in slight contradiction to the previous study conducted by Abdul-Rahman 
and her colleagues on unfractionated serum samples (Abdul-Rahman et al., 2007).  In 
their analysis of serum samples, Abdul-Rahman el al. (2007) reported the differential 
expression of five high abundance proteins found in patients with ECa compared to 
controls.  In their study, the expression of serum ZAG was not significantly different 
between the ECa patients and the controls, whilst the data of the present study showed 
higher expression of urinary ZAG in the ECa patients.  Urine is the filtration of 
plasma/serum by the glomerulus, which is a selective process based on dimension, 
charge and configuration of the protein.  Therefore, the divergence of data was probably 
due to the different types of samples used for both studies. 
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4.3  Purification of CMB and CGB lectins 
           Prior to the analysis of urinary glycoproteins, CMB and CGB lectins were 
isolated from the crude extracts of seeds obtained from the champedak fruit (Artocarpus 
integer).  Before the isolation of the lectins, the champedak seeds were treated with 
several procedures in order to obtain optimum amount of lectins.  Firstly, the seed coats 
were peeled off, prior to grinding.  The reason for removing the seed coats was to 
remove impurities that might be present.  Then, the seeds were homogenized to break 
the cell walls.  This was followed by the centrifugation of the crude extracts, which 
eliminated the cellular debris.  The crude lectins were precipitated with ammonium 
sulphate at 60% saturation.  The hydrophilic property of the proteins was disrupted 
when sufficient ionic strength was exerted by an appropriate concentration of 
ammonium sulphate to the proteins. 
 
   The mannose and galactose sugar affinity chromatography columns were used to 
purify the CMB and CGB lectins, respectively, from the crude lectin extracts (Hashim 
et al., 1991; Lim et al.,  1997).  The unbound fractions from galactose sugar affinity 
chromatography columns were subjected to mannose sugar affinity chromatography 
column to isolate the CMB lectin.  The lectins were eluted out when 0.8 M of mannose 
or galactose were applied into the mannose or galactose sugar affinity chromatography 
columns, respectively.  This is due to the higher attraction of the lectins to the high 
concentration of sugars compared to the immobilized sugars. 
 
   The purity of the lectins was assessed in order to avoid presence of other 
proteins, which might affect the subsequent experiments.  Both lectins were reduced 
and subjected to 18% SDS-PAGE for separation.  Under the reducing condition, the 
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CMB lectin was resolved into a distinctive band, with molecular weight of 
approximately 14 kDa, while the CGB lectin was resolved into two bands, with 
approximate molecular weights of 14 kDa and 16 kDa.  The appearances of the bands 
for the respective lectins were comparable with their proposed subunit (Lim et al., 1997; 
Abdul Rahman et al., 2002).  The purity of the lectins were confirmed where there was 
no additional band detected in the SDS-PAGE gel.  
 
4.4  2-DE lectin blot analysis of urinary proteins obtained from controls and 
patients with ECa, OCa and CCa 
The present study not only examined the altered expression of the urinary 
proteins but was also extended to the study of their glycosylation.  Glycosylation is one 
of the posttranslational modifications that occur when an oligosaccharide binds to the 
suitable binding site of a protein.  It greatly alters the physical properties of proteins and 
their biological functions such as stabilizing the protein orientation, maintaining 
homeostasis of the cellular processes and acting as functional molecules. Many 
evidences indicate that abnormally glycosylated proteins are implicated with cancer 
progression (Abdul-Rahman et al., 2007; Dai et al., 2009; Dennis et al., 1999; Fujimura 
et al., 2008; Mu et al., 2012).  Thus, the study of the altered glycosylation could provide 
a meaningful information of  its roles in cancer development. 
 
   The current study, which involved patients with ECa, CCa and OCa, unraveled 
the glycosylation of urinary proteins using the CGB and CMB lectins as probes.  The 
lectin approach allowed the validation of the previous 2-DE silver-stained data and the 
detection of additional proteins that were either not detected or not well resolved in the 
2-DE silver-stained method (Abdul-Rahman et al., 2007).  In addition, it was also 
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possible to determine whether urinary proteins were aberrantly glycosylated by 
comparing the 2-DE lectin blots with the similar 2-DE silver-stained urinary profiles of 
controls and patients. 
 
   To date, N- and O-glycosylated urinary protein maps have not been established, 
even though a number of complete urinary protein maps have been reported since year 
1979 (Anderson et al., 1979; Candiano et al., 2010).  Through the present study, two 
different comprehensive O- and N-glycosylated urinary protein profiles have been 
successfully developed using the enzyme conjugated CGB and CMB lectins, 
respectively.  When the 2-DE separated proteins were transferred onto nitrocellulose 
membranes and probed with enzyme-conjugated CGB lectin, profiles consisting of only 
O-glycosylated urinary proteins were obtained.  Comparative densitometry analyses 
were made between 2-DE O-glycosylated protein profiles generated from the urine 
samples of the controls and patients with ECa, OCa and CCa.  The significant altered 
levels of a single O-glycoprotein, which were subsequently identified as a 51 kDa 
fragment of NEB via on-membrane digestion followed by mass spectrometry and 
database searching, were demonstrated in the O-glycosylated urinary protein profiles of 
patients with ECa.  The expression of urinary NEB was not significantly different 
between patients with CCa or OCa compared to the controls. 
 
However, in patients with CCa, none of the O-glycosylated urinary proteins that 
were detected was significantly different from those of the controls.  In case of the OCa 
patients, reduced levels of KNG were detected compared to the controls. And this 
provides further confirmation of an earlier work performed by silver staining of 2-DE 
gels (Abdullah-Soheimi et al., 2010).  In addition, LRG and CLU were also found to be 
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differentially expressed in patients with OCa, although this was not detected earlier 
(Abdullah-Soheimi et al., 2010).   NEB, LRG and CLU may not have been detected or 
well resolved in the earlier 2-DE experiments probably because of their relatively low 
amount in the urine samples.   
 
          A profile consisting of only N-glycosylated urinary proteins was obtained when 
2-DE separated proteins were probed with enzyme conjugated CMB lectin.  
Comparison of N- and O-glycosylated urinary proteins profiles showed that HPX, 
IGHA1, KNG, LRG, CLU, ITIH4, AMBP, TAGLN and HSPG2 were present in both 
profiles.  These proteins contain both consensus sequence of Asn-X-Ser(Thr) and serine 
or threonine residues for the binding of N-acetylglucosamine and N-
acetylgalactosamine, respectively.  When image analysis of the 2-DE separated N-
glycosylated urinary protein profiles was made between the controls and patients with 
ECa, the spots of ZAG and AAG appeared more intense in the patient samples.  These 
findings are comparable to the results that were established by subjecting the 2-DE gels 
to silver-staining, which were discussed earlier.   
 
Similarly, the intensities of ZAG and AAG were also much higher in the N-
glycosylated urinary protein profile of patients with OCa but this was not earlier 
detected in the silver-stained gel analysis (Abdullah-Soheimi et al., 2010).  The 
noticeable difference in the intensities of both proteins between the N-glycosylated 
protein profiles and those generated by silver-stainining from the patients with OCa 
indicated that these proteins may be differentially glycosylated.  This may be attributed 
to the increase or higher exposure of the mannosyl residues of the N-glycans of the 
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urinary ZAG and AAG, which led to the strong interaction of the CMB lectin to the 
glycans side chains of the proteins, although this requires further validation work.  
 
  Similar to those observed in the O-glycosylation profiles of patients with OCa, 
the altered expression of KNG, CLU and LRG in the N-glycosylated urinary protein 
profiles of patients with OCa was demonstrated in the present study.  This implied their 
altered levels were most probably caused by their differential expression in the cancer 
state, although their fold changes were different in both profiles.  In the case of HP, its 
differential expression was detected only with the CMB lectin in the N-glycosylation 
profiles of the OCa patients.  When the protein spot was subjected to MS/MS analysis, 
its peptide sequence was identified as β chain of HP with high confidence.  The current 
findings of the altered levels of LRG, CLU and HP β chain was compatible with the 
previous study on the sera of OCa (Chen et al., 2008).  It can be postulated that the 
increase of proteins in the urine of OCa patients may reflect the change that occurred in 
the serum.  Similar to the O-linked glycosylation profile, no significant changes were 
observed in the N-glycosylation profiles of patients with CCa as compared to that of the 
controls. This may due to the large discrepancy of protein levels in the urine samples of 
CCa patients.   
 
4.5  LC-MS/MS analysis of bound fractions of urinary glycoproteins obtained 
from CGB and CMB lectin affinity chromatography  
           Low abundance proteins could deliver a vast amount of clinical information 
regarding the pathogenesis of cancer.  Owing to the enormous complexity of the urinary 
proteome, they are normally masked by the high abundance proteins, making them 
difficult to be detected.  To a certain extent, lectin-affinity chromatography allows the 
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detection of low abundance proteins by reducing the complexity of the protein mixture 
where only glycosylated proteins was isolated.  Glycoprotein enrichment was used 
because up to 50% of the human proteins are glycosylated (Budai et al., 2009).  
However, unlike lectin-blotting, lectin-affinity chromatography captures glycoproteins 
in their native form, in which the glycoprotein functional structures are preserved.  
Therefore, this method would selectively bind to proteins with exposed glycans.  
   
The analysis of samples using LC-MS/MS is highly sensitive and applicable for 
high throughput assessment although it is rather costly.  At present, several reports have 
addressed the study of the N-glycosylated proteins in the urine using the lectin 
enrichments methods and followed by LC-MS/MS analysis.  Yang and colleagues 
developed a glycoproteomic strategy for bladder cancer biomarker discovery using 
dual-lectin affinity enrichment of urinary N-glycosylated proteins followed by LC-
MS/MS (Yang et al., 2011).  They discovered the elevation of alpha-1-antitrypsin in the 
urine of bladder cancer patients after quantifying urinary proteins using label free 
spectral counting method and validating it with ELISA. This suggested that alpha-1-
antitrypsin could be a potential complementary biomarker for bladder cancer.  At the 
same time, similar glycoproteomic approach established by Vivekanandan-Giri et al. 
(2011) was able to identify a few differentially expressed N-glycosylated proteins in the 
urine of patients with chronic kidney disease (Vivekanandan-Giri et al., 2011).  Wang et 
al. (2006) profiled urinary N-glycosylated proteins of healthy controls by using Con A 
lectin affinity chromatography with LC-MS/MS analysis.  To the best of our 
knowledge, the current study is the first to focus on O-glycosylated urinary proteins by 
combining lectin enrichments and mass spectrometry analysis.  
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In this study, the CGB and CMB lectins were used for protein enrichment. LC-
MS/MS analysis of CGB and CMB lectins bound fractions gave rise to the 
identification and characterization of 36 and 46 urinary proteins with high confidence, 
respectively.  Almost all of the proteins detected previously from 2-DE silver-stained 
and lectin blot were detected in the bound fractions except CLU.  Apart from 
identifying the proteins, the subcellular localizations of these proteins were also 
determined with the SWISS-Prot annotations.  Most of the identified proteins originated 
from secreted proteins.  Therefore, it is possible that these proteins may not be part of 
urine, but rather secreted from the host organ or tumor itself and excreted together with 
the urine.  Meanwhile, a number of membrane proteins have also been resolved from 
both the lectin enrichments of bound fractions coupled with LC-MS/MS analysis as 
they were not able to be detected in previous 2-DE approach because of their low 
solubility.  In terms of glycosylation, some proteins were not annotated to be 
glycosylated in the Uniprot database.  Nevertheless, they were predicted as potentially 
glycosylated when their sequences were analyzed with NetOGlyc 3.1 
(http://www.cbs.dtu.dk/services/NetOGlyc/) and NetNGlyc 1.0 
(http://www.cbs.dtu.dk/services/NetNGlyc/).  Both servers can determine whether the 
consensus sequences may be recognized by the glycosyltransferase as the acceptor site 
for glycans (Julenius et al., 2005).  
 
  In the recent years, label free relative quantitation by spectral counting has been 
demonstrated to correlate with protein abundances (Liu et al., 2004). Since all altered 
proteins detected previously were secreted proteins, it could be assumed that their levels 
should be equal to their glycosylated forms (Chen et al.,  2011).  Hence, their total 
number of identified MS/MS spectra were counted and compared.  However, an issue 
that arised from the spectra counting approach was that small proteins tend to have 
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fewer peptides identified per protein compared to large proteins. Thus, the spectra of 
those particular proteins were normalized with normalized spectral abundance factor 
(NSAF) in order to prevent false quantitative result caused by the discrepancy of the 
proteins’ length or sequence (Florens et al., 2006; Zybailov et al., 2006). 
Correspondingly, the spectral counting data of LRG from CGB lectin and KNG from 
CMB lectin bound fractions validated their differential levels observed in the OCa 
patients’ urine. For HP, seven out of 11 spectra detected in the CMB lectin 
chromatography bound fractions of OCa sample belonged to the β-chain, which was 
comparable to the differential expression that was observed in the CMB lectin blot 
analysis.  Apart from that, the concentrations of ZAG and AAG detected in the bound 
fractions of the CMB lectin column from OCa patients were found to be unchanged.  
This  conceived the possibility of aberrant N-glycosylation of both the proteins.  There 
was a notable difference in Western blotting-CMB lectin analysis with the current result 
for these proteins.  Nonetheless, this hypothesis was not conclusive as further study on 
their N-glycan structures are required to prove it.   
 
In the CMB lectin bound fractions of patients with ECa, both the patient:control 
expression ratios of urinary ZAG and AAG were more than 1.9 fold.  This is compatible 
with the altered expression of both the proteins that was detected in the previous 2-DE 
experiments using silver staining (Section 3.5.1).  The aberrant expression of CD59 in 
the three cohorts of cancer was affirmed by detection of two corresponding spectra 
exclusively in the CMB bound fractions of the controls but not in the patients 
(Abdullah-Soheimi et al., 2010; Abdullah-Soheimi, 2012; Mu et al., 2012).  Similar 
analysis on the CGB bound fractions of ECa further confirmed the low level of the NEB 
fragment in the urine of the patients.  The deviation protein expression between 
individual subjects lead to the disparity of the magnitude of fold changes for the altered 
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proteins between the spectral counting method and 2-DE profiles.  Therefore, there is a 
need to further validate the present biomarker candidates using large scale 
investigations using a simpler technique such as ELISA for the clinical purpose of early 
detection of ECa, OCa and CCa.    
 
4.6  Biological functions of urinary proteins that were differentially expressed 
           In this section, the urinary glycoproteins whose levels were altered in patients 
with ECa, OCa and CCa that were detected in the present study is discussed with 
reference to their structures, biological functions and possible reasons for their abnormal 
expression.  Apart from that, the possibility of the urinary proteins being aberrantly 
glycosylated is also discussed.   
 
4.6.1  Zinc alpha-2 glycoprotein (ZAG)   
ZAG is a glycoprotein with molecular weight of approximately 40 kDa, secreted 
by a variety of epithelial cells (Hale et al., 2001).  It is generally described as a 
stimulator for lypolysis although its function may include as a carrier protein, 
immunoregulator and cell adhesion molecule (Hassan et al., 2008).  ZAG may also play 
a role in cancer where its altered expression in the sera was widely documented in 
patients with prostate, breast and cervical cancers (Hale et al., 2001; Abdul-Rahman et 
al., 2007; Dubois et al.,  2010).  The protein may be associated with pathways involving 
adipokines and estrogen, and its differential expression in patients with ECa was 
postulated to be due to the changes in the levels of these factors (Dubois et al., 2010).  
In addition, ZAG has also been suggested to play a role in the development of cancer 
cachexia, one of the stimulator of carcinogenesis (Gordon et al.,  2005). 
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4.6.2  Alpha-1 acid glycoprotein (AAG) 
           AAG, also known as orosomucoid, is a heterogeneous protein with a variety of 
important roles in binding and transportation of endogenous basic substances and drugs, 
and in an immunomodulatory function (Budai et al., 2009).  It is also a positive acute 
phase protein as its concentration can elevate several folds during inflammation.  Its up-
regulation in serum was documented in several types of cancer including ECa and OCa 
(Tosner et al., 1988; Wang et al., 2011).  It is a highly N-glycosylated, with the glycans 
constituting about 45% of its molecular mass of 41 kDa (Herve et al., 1998). Since the 
intensity pattern of the protein spots detected in the 2-DE gel and CMB lectin blot was 
comparable in patients with ECa, it could be concluded that the glycosylation of the 
protein was most probably normal.  On the other hand, the possible changes in N-
glycosylation of AAG was suggested in the patients with OCa in the present study when 
the expression of the protein appeared to be altered in the CMB lectin blot but not in 
silver stained 2-DE gels (Abdullah-Soheimi et al., 2010).  And this is consistent with 
the findings from Saldova and colleagues, which indicated the changes in the AAG 
glycoforms, which contributed to changes of the serum glycome of patients with OCa 
(Saldova et al., 2007). 
 
4.6.3  CD59  
          CD59, also known as protectin, is a cell surface protein that functions to inhibit 
the membrane attack complex of the complement pathway.  The present study has 
demonstrated the decreased in excretion of CD59 in the urine of patients with the three 
groups of cancer patients studied.  A similar excretion profile of CD59 in the urine had 
been previously reported in pancreatic ductal adenocarcinoma and bladder cancer 
(Kreunin et al., 2007; Weeks et al., 2008).  Its altered excretion in the serum/plasma has 
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never been reported even though the altered expression of CD59 in malignant tissues 
and in the urine had been observed (Murray et al., 2000).  This might be due to its low 
solubility and thus difficult to be detected in the serum and plasma.  The reason behind 
the reduced expression of CD59 in gynaecological cancers is not known, but the 
depletion of CD59 by cancer cells to resist the attack of complement might explain why 
less of this protein are being solubilized and excreted in the urine (Abdullah-Soheimi et 
al., 2010). 
 
4.6.4  Nebulin (NEB) 
            Nebulin, a protein with a deduced molecular weight of 772.9 kDa, functions as a 
template for polymerization of actin (Pappas et al., 2011).  The protein is expressed 
predominantly in the thin filaments of striated muscle. It is known to be glycosylated, 
although the precise structure of its glycan moiety has never been characterized (Madera 
et al., 2006).  Hence, the result of the CGB lectin analyses performed in this study is a 
form of evidence that nebulin is O-glycosylated. The low molecular weight of the 
nebulin spot detected in the 2-DE experiments is indicative of a truncated or cleaved 
protein. The reduced levels of tissue nebulin are commonly associated with myopathy 
(Ottenheijm et al., 2010).  However, its increased levels in the pancreatic juice are 
believed to be associated with the cellular turnover in patients with pancreatic cancer 
(Park et al., 2011).  To the best of our knowledge, there is no previous report on the 
detection of nebulin or its fragment in the urine, but the protein has been detected in 
other biofluids such as serum and pancreatic juice (Tanaka et al., 2006; Park et al., 
2011).  
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4.6.5  Leucine rich alpha-2 glycoprotein (LRG)  
           LRG is a secreted protein with five glycosylation sites, which contains an O-
linked oligosaccharide and four N-linked oligosaccharides chains (Rodriguez-Pineiro et 
al., 2004).  It is composed of leucine rich repeats, in which 17% of its total amino acid 
composition are leucine residues.  Its actual functions are still unknown, although 
numerous studies have reported its roles in cell adhesion, granulocytic differentiation, 
cell migration, cell survival, protein interaction and signal transduction (Andersen et al., 
2010).  In addition, it was also proposed as an acute phase protein when its level was 
reported to be elevated in microbial infections and certain cancers including OCa 
(Andersen et al., 2010).   LRG is mainly produced by the liver cell in response to OCa, 
but its production by the OCa cells alone had also documented (Boylan et al., 2010).  
Thus, the secretion of LRG by the liver cells and OCa cells may contribute to the 
increase of LRG level excreted in urine from OCa patients. 
 
4.6.6  Clusterin (CLU) 
            CLU, also known as apolipoprotein J, is a highly conserved heterodimeric 
secreted glycoprotein.  It comprises 449 amino acids with two chains (α and β) of 
approximately 40 kDa each, linked by disulfide bonds.  The protein has been implicated 
in various physiological processes, including lipid transportation, immune system 
regulation, membrane recycling, senescence, DNA repair, cell aggregation and cell 
adhesion (Rosenberg and Silkensen 1995; Trougakos and Gonos 2002).  Moreover, the 
expression of CLU has also been reported to correlate with cell stress response, 
tumorigenesis and apoptosis, particularly in protecting cancer cells from complement-
mediated lysis (Shannan et al.,  2006; Nafee et al., 2012).  The overexpression of CLU 
has been described in several types of cancers including OCa but the decrease of its 
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expression had been observed in prostate cancer and esophageal squamous cell 
carcinoma (Redondo et al., 2000; Zhang et al., 2003; Doustjalali et al., 2004; Albert et 
al., 2007; Chen et al., 2008; Rizzi and Bettuzzi 2009).  The present data derived from 
the profiles of glycoproteins detected using CGB and CMB lectins have demonstrated 
the increased levels of CLU in the urine of OCa patients and its expression was further 
statistically confirmed with competitive ELISA as well as Western blotting using 
monoclonal anti-CLU.  In addition, the present study demonstrates for the first time that 
CLU may contain O-glycans since the protein was shown to interact with the CGB 
lectin.  Based on its known structure, CLU may contain one O-glycan moiety at its 
potential O-glycosylation site at the amino acid position of 403 (Kapron et al., 1997).  
On the other hand, the CLU from OCa patients may also be possibly differently O-
glycosylated.   
 
4.6.7  Kininogen (KNG) 
           KNG is a protein containing two isoforms produced by alternative mRNA 
splicing (Takagaki et al., 1985).  The KNG that was observed in the present study was 
actually the light chain component of cleaved high molecular weight kininogen.  
Numerous studies of KNG have demonstrated that it was significantly reduced in 
patients with gastrointestinal cancer, breast cancer and cervical cancer (Roeise et al., 
1990; Doustjalali et al., 2004; Abdul-Rahman et al., 2007).  The present data further 
confirmed its expression level in the urine of the OCa patients, as reported by Abdullah-
Soheimi et al. (2010).  Reduced levels of KNG in the urine of OCa patients may reflect 
its anti-angiogenic property and inhibitory action on the proliferation of endothelial 
cells (Liu et al., 2008).   
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4.6.8  Haptoglobin (HP) 
           HP is an acute phase protein existing as a disulfide-linked α2β2 heterotetramer.  
Polymorphism of HP arises from the combination of different α-chains with identical β 
-chains (Zhao et al., 2007).  These two chains are formed from the cleavage of a 
common precursor polypeptide during post-translational modification (Haugen et al., 
1981).  The main function of HP is to bind free hemoglobin for protection from 
oxidative stress and to facilitate the hemoglobin uptake by the hemoglobin scavenger 
receptor CD163 (Zhao et al., 2007; Kang et al., 2011).  Besides, it also plays important 
roles in angiogenesis, the regulation of epidermal cell transformation, the inhibition of 
prostaglandin synthesis and reverses cholesterol transportation (Abdullah et al., 2009). 
The production of HP is mainly by the liver in large amount in response to the 
stimulation of infections, inflammations and various malignant diseases, including OCa, 
lung cancer, breast cancer, pancreatic cancer, esophageal squamous cell carcinaoma and 
bladder cancer (Zhao et al., 2007).  The present study has demonstrated the differential 
expression of HP-β chain from patients with OCa detected with CMB lectin, and this is 
in agreement with the study done by Ahmed et al (2004).  However, the failure of HP-α 
chain to be detected with the same lectin was expected since none of the consensus 
sequences of N-glycosylation site is located in the α-chain (Fujimura et al., 2008). 
Although the elevation of HP-β chain in OCa was most probably related to the acute 
phase response, it is plausible that the elevation was also due to its action as a non-
specific immune suppressor of cancer (Abdullah et al., 2009).  Furthermore, as in the 
case of AAG that was mentioned earlier (Section 4.6.2), the increase of HP-β chain 
level could also account for the changes in the serum glycome such as the SLe
x
 
structure (Saldova et al., 2007). 
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4.7  SELDI-TOF analysis of urinary glycopeptides of patients with ECa, OCa 
and CCa 
           SELDI-TOF has emerged as one of the most powerful tool for detection of 
potential biomarkers for diseases.  In the technique, the SELDI-TOF protein chip 
selectively captures specific proteins, which thereafter were resolved by mass 
spectrometry.  The application of SELDI-TOF has numerous advantages including its 
ease of use, high-throughput application and its capability to analyze small amounts of 
multiple samples in a short time.  However, SELDI-TOF is not sensitive towards high 
molecular weight proteins and thus confined to the analysis of low molecular weight 
peptides.  Furthermore, it is also unable to precisely identify proteins from the peak 
detected. 
 
The serum of patients with ECa, OCa and CCa has been widely explored using 
the SELDI-TOF technology.  From the serum spectra generated on the weak cation 
exchange (WCX2) protein chips, several researchers have previously identified 
potential biomarkers for ECa, OCa and CCa (Zhang et al., 2006; Xia et al., 2008; Zhu et 
al., 2008).  Nevertheless, urine samples have never been explored using the SELDI-
TOF for these cancers although studies on the urine of patients with bladder cancer have 
been previously reported (Chen et al., 2010). 
 
In the present pilot study, a method utilizing immobilized CGB and CMB lectins 
preactivated protein chip array was developed to selectively capture O- and N-
glycosylated urinary proteins for SELDI-TOF analysis.  In view of the limitation of 
SELDI-TOF on the analysis of low molecular weight peptides, trypsin-digested urinary 
glycopeptides were analysed instead of crude urinary glycoproteins.  Analysis of lectin-
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captured glycopeptides generates profiles comprising subsets of the whole 
glycoproteome, which are selective to the type of glycans they contain.  Therefore, the 
CGB and CMB lectins pre-activated protein chip assays that were developed in the 
present study were not only able to identify the urinary glycoproteins that may be 
differentially expressed, but also to determine the possibility of detecting proteins that 
may be aberrantly glycosylated.   
 
In case of O-linked urinary glycopeptides captured by the CGB lectin coupled 
Protein Chip array, glycopeptides mass with m/z 2138 and 3656 were autoselected to 
form the decision tree by the Biomarker Pattern Software.  However, the intensity of the 
peaks were not significantly different between the cancers, which was most probably 
due to the small number of samples used for the statistical analysis.   
 
Similarly, when N-linked urinary glycopeptides were captured by the CMB 
lectin coupled Protein Chip array, glycopeptides mass with m/z 1201and 1449 were 
autoselected to form the decision tree by the Biomarker Pattern Software.  The peak m/z 
1201 apparently has a strong discriminatory power to distinguish OCa from CCa and 
ECa and its sensitivity and specificity were 100%.  It is therefore a potential biomarker 
candidate for OCa.    On the other hand, the peak m/z 1449 had the capability of 
discriminating ECa from the other two types of cancers.  When peaks m/z 1201 and 
1449 were subjected to statistical analysis using EDM, they were discerned to be 
significantly different between each type of cancer.  Hence, in the present preliminary 
study, a combination of the two glycopeptides peaks that were detected using the CMB 
lectin coupled Protein Chip suggest the possibility of using the lectin-based SELDI-
TOF assay to determine the three different types of gynaecological cancers although this 
Discussion 
142 
 
needs to be further validated using epidemiologically-represented sample sizes.  In 
addition, the two glycopeptides peaks can be identified using available bioinformatic 
tools in the future.   
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CHAPTER 5: CONCLUSION 
        Subjecting urine samples of control subjects and patients with ECa to the 
analysis by 2-DE in the present study showed the significant differential expression of 
ZAG, AAG and CD59.  When the  analysis was repeated using CGB lectin to detect O-
glycosylated proteins, NEB was further detected to be significantly reduced in the ECa 
patients compared to the controls.  A similar analysis of the urinary O-glycosylated 
protein profiles of patients with OCa demonstrated the altered expression of KNG, CLU 
and LRG.  In case of patients with CCa, however, the expression levels of all O-
glycosylated proteins appeared to be comparable to those of the controls.   
 
  When the CMB lectin was used to generate a 2-DE profile consisting of 
exclusively N-glycosylated proteins, significant increase of ZAG and AAG was 
detected in the urine of ECa patients, which is similar to the results that was generated 
by silver staining of the 2-DE gels.  In case of the OCa patients, comparative analysis of 
the N-glycosylated protein profiles showed overexpression of AAG, ZAG, LRG, CLU 
and HPβ chain but decreased in the levels of  KNG.  Conversely, the expression of N-
glycosylated urinary proteins was comparable between the controls and CCa patients.   
 
Analysis of bound fractions obtained from immobilized CGB lectin affinity 
chromatography by LC-MS/MS generated a list of O-glycosylated/potentially O-
glycosylated proteins.  The label free quantification analysis demonstrated the altered 
levels of LRG and NEB in patients with OCa and ECa, which is similar to the above-
mentioned earlier findings by Western blot.  Similarly, when immobilized CMB lectin 
affinity chromatography was used to isolate native N-glycosylated proteins, spectral 
counting showed altered levels of AAG and ZAG for patients with ECa and OCa and 
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differential expression of KNG and HPβ chain for OCa patients. These are also in 
agreement with the earlier findings by Western blot. In addition the LC-MS/MS 
analysis detected presence of CD59 peptides, which only appeared in the CMB lectin 
bound fractions from the control subjects, but not in the bound fractions collected from 
patients with ECa, OCa and CCa. 
           
Analysis of the CMB lectin captured urinary glycopeptides of control subjects 
and patients with ECa, OCa and CCa by SELDI-TOF unraveled two peaks m/z 1201 
and 1449 as group discriminators.  Similar analysis using Biomarker Wizard performed 
on the CGB lectin captured urinary glycopeptides of control subjects and three groups 
of cancer patients determined m/z 2138 and 3656 as potential group discriminator.   
           
   The data of this study are suggestive of the potential use of urinary proteins such 
as ZAG, AAG, NEB, KNG, LRG, CLU, HPβ chain and CD59 as complementary 
biomarkers for ECa, OCa and CCa.  Diagnostic kits using antisera against the proteins 
may be easily generated and used in the clinical setting.  However, this requires further 
extensive validation on clinically representative populations.  Such a study cannot be 
possibly performed using the present gel-based proteomic and lectin-based proteomic 
analyses approaches since they are laborious and expensive.  Nevertheless, with the 
identification of the potential urinary biomarkers in the present study, validation is 
easily carried out in a large-scale investigation using assays like the protein array or 
multiplex ELISA. 
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